

# Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Received: 16 May 2023

Accepted: 15 August 2023

Published online: 11 September 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males) with HIV-1 on ART were randomized to (1) placebo/placebo, (2) lefitolimod (TLR9 agonist)/placebo, (3) placebo/broadly neutralizing anti-HIV-1 antibodies (bNAb) or (4) lefitolimod/bNAb. ART interruption (ATI) started at week 3. Lefitolimod was administered once weekly for the first 8 weeks, and bNAb were administered twice, 1 d before and 3 weeks after ATI. The primary endpoint was time to loss of virologic control after ATI. The median delay in time to loss of virologic control compared to the placebo/placebo group was 0.5 weeks ( $P = 0.49$ ), 12.5 weeks ( $P = 0.003$ ) and 9.5 weeks ( $P = 0.004$ ) in the lefitolimod/placebo, placebo/bNAb and lefitolimod/bNAb groups, respectively. Among secondary endpoints, viral doubling time was slower for bNAb groups compared to non-bNAb groups, and the interventions were overall safe. We observed no added benefit of lefitolimod. Despite subtherapeutic plasma bNAb levels, 36% (4/11) in the placebo/bNAb group compared to 0% (0/10) in the placebo/placebo group maintained virologic control after the 25-week ATI. Although immunotherapy with lefitolimod did not lead to ART-free HIV-1 control, bNAb may be important components in future HIV-1 curative strategies. ClinicalTrials.gov identifier: [NCT03837756](https://clinicaltrials.gov/ct2/show/study/NCT03837756).

Human immunodeficiency virus type 1 (HIV-1) infection persists mainly in CD4<sup>+</sup> T cells as a long-lived HIV-1 reservoir. Continuous lifelong antiretroviral therapy (ART) is needed to suppress viral replication and prevent disease progression. When ART is stopped, viral replication quickly resumes, leading to rebound of plasma viremia within weeks in almost all individuals<sup>1–5</sup>.

Many HIV-1 curative strategies aim to enhance HIV-1-specific immunity as a means to achieve ART-free HIV-1 virologic control. Until recently, HIV-1 cure trials have typically involved people with HIV-1 (PWH) on long-term suppressive ART, which is continued during the therapeutic interventions<sup>6</sup>. In these individuals, the level of

HIV-1 antigen both in blood and tissues is extremely low due to the effective modern ART regimens. The scarcity of antigen may explain why experimental immunotherapies, such as cytokines and other immunostimulatory agents, have had limited impact on HIV-1-specific immunity and viral persistence in clinical trials<sup>7,8</sup>.

One promising immunostimulatory agent is lefitolimod (MGN1703), a dumbbell-shaped DNA molecule that triggers Toll-like receptor (TLR) 9 signaling in human plasmacytoid dendritic cells (pDCs) and B cells<sup>9,10</sup>. Moreover, TLR9 agonists have been shown to enhance potent antibody-dependent cellular cytotoxicity (ADCC) *in vitro*<sup>11</sup>. *In vivo*, TLR9 agonist administration among PWH on long-term

suppressive ART induced activation of pDCs, leading to potent upregulation of antiviral immune responses<sup>12–15</sup>. During TLR9 agonist treatment, the proportion of activated cytotoxic (CD56<sup>dim</sup>CD16<sup>+</sup>) natural killer (NK) and CD8<sup>+</sup> T cells expanded in blood<sup>12,13</sup> and lymph nodes<sup>14</sup>. This might facilitate killing of infected cells, as ex vivo studies have shown that priming of effector cells, such as cytotoxic T lymphocytes (CTLs) and NK cells, enhances their ability to recognize and eliminate antigen-expressing infected cells<sup>16–20</sup>. Finally, TLR9 agonist treatment may directly impact the HIV-1 reservoir through cytokine release or cell-to-cell-mediated activation<sup>21</sup>. In a small clinical trial, an increased frequency in viral blips during lefitolimod administration was observed among PWH on ART, suggesting that lefitolimod may have a latency-reversing effect on the HIV-1 reservoir<sup>12</sup>.

The immunological effects of lefitolimod could potentially be boosted either by administering the drug in the presence of higher antigen load or by co-administration with broadly neutralizing anti-HIV-1 antibodies (bNAbs), such as 3BNC117 and 10-1074, which recognize non-overlapping epitopes on the HIV-1 envelope protein gp120 (refs. 22,23). In support of the latter concept, non-human primate (NHP) studies have shown that administration of a TLR7 agonist, which, similarly to a TLR9 agonist, activates pDCs and triggers antiviral immune responses, in combination with bNAbs led to ART-free virologic control in a large proportion of animals during ART interruption (ATI)<sup>24–26</sup>. In phase 1–2 clinical trials, repeated administration (3–8 doses) of the combination of 3BNC117 and 10-1074 maintained viral suppression for ~13 weeks after last bNAb infusion when administered instead of ART<sup>27–29</sup>. Finally, owing to Fc-mediated engagement of effector and antigen-presenting cells, bNAbs independently exert immunomodulatory effects, and bNAb treatment has been shown to augment HIV-1-specific T cell immunity both in viremic NHPs and in humans<sup>6,30–32</sup>.

Collectively, these observations led us to hypothesize that lefitolimod alone or in combination with two doses of 3BNC117 and 10-1074 administered in the setting of ATI could potentially enhance elimination of infected cells and boost HIV-1-specific CD8<sup>+</sup> T cell immunity, leading to ART-free virologic control (Fig. 1a)<sup>33</sup>. To address this hypothesis, we conducted an investigator-initiated, randomized, placebo-controlled, double-blinded phase 2a trial to determine the impact of lefitolimod and 3BNC117 + 10-1074 on virologic control among PWH undergoing ATI. Secondary endpoints were safety and viral rebound kinetics.

## Results

### Participants and follow-up

Eligible individuals were recruited from 12 April 2019 to 5 November 2021, and follow-up concluded on 9 June 2022. Of 117 individuals who were screened for sensitivity to 3BNC117 and 10-1074 by phenotypic or sequence-based analysis, 46 participants were enrolled in the study, of whom three withdrew consent for personal reasons and did not receive the random allocation treatment (Fig. 1b and Extended Data Fig. 1). Of the remaining 43 participants, 10 were randomly allocated to placebo/placebo, 10 to lefitolimod/placebo, 11 to placebo/bNAb and 12 to lefitolimod/bNAb. Lefitolimod (120 mg) or placebo was dosed subcutaneously (s.c.) once weekly for 8 weeks starting 2 weeks before the ATI and ending at the beginning of week 6 of the ATI (Fig. 1a). 3BNC117 (30 mg kg<sup>-1</sup>) and 10-1074 (20 mg kg<sup>-1</sup>) or placebo were given as sequential intravenous (i.v.) infusions the day before starting the ATI and 3 weeks into the ATI. One participant in the placebo/bNAb group discontinued the ATI and re-started ART after an infusion-related reaction during the second bNAb infusion (Fig. 1b). This person was included in the analyses. No participants were lost to follow-up.

The four randomization groups were overall well balanced on key demographic and genetic parameters (Table 1 and Extended Data Table 1). Study participants were mainly white (87%) and male (85%). Median age at enrollment was 50 years (interquartile range (IQR): 41–54), and median time since HIV-1 diagnosis was 10 years (IQR: 6–15). Participants had been on ART for a median of 8 years (IQR: 5–12), and the median


CD4<sup>+</sup> T cell count was 801 cells per mm<sup>3</sup> (range: 507–2,100) (Extended Data Table 1). Approximately three-quarters of the individuals (72%) had HIV-1 subtype B; the remaining participants had other HIV-1 subtypes (Table 1 and Extended Data Table 1). Across the four groups, human leukocyte antigen (HLA) class I alleles associated with rapid HIV-1 progression (that is, B\*07 and B\*35) or elite control (that is, B\*27, B\*57 and B\*58) were represented in 43% and 11% of the participants, respectively (Extended Data Table 1).

### Plasma HIV-1 RNA kinetics after ART interruption

To determine the impact of the interventions on ART-free virologic control, all participants underwent a closely monitored 25-week ATI. The study's primary endpoint was time from stopping ART to the date of meeting the criteria for loss of virologic control (defined as 4 weeks with sustained plasma HIV-1 RNA  $\geq 1,000$  copies per milliliter or two consecutive measurements  $>100,000$  copies per milliliter). All participants in the placebo/placebo group experienced loss of virologic control, which occurred at a median of 4.5 weeks (IQR: 3.0–11) after stopping ART (Fig. 2a). In the lefitolimod/placebo group, median time to loss of virologic control was 5.0 weeks (IQR: 4.0–6.0) (Fig. 2b). One individual in this group had partial ART-free virologic control with viremia ranging from  $<20$  to 5,500 copies per milliliter throughout the ATI (Fig. 2b). In the placebo/bNAb group, median time to loss of virologic control was 17 weeks (IQR: 11–25) (Fig. 2c). However, four of 11 participants (36%) maintained virologic control during the 25-week ATI. In the lefitolimod/bNAb group, the median time to reach criteria for viral rebound was 14 weeks (IQR: 10–17) (Fig. 2d). One individual had partial ART-free virologic control, with viremia ranging from  $<20$  to 65,100 copies per milliliter during the ATI. All six individuals with either partial or complete ART-free virologic control tested negative for antiretroviral drugs in plasma at week 25 of the ATI. One partial controller in the placebo/bNAb group had a protective HLA class I allele (ID601: HLA\*B27) (Extended Data Table 1), and one started ART less than 6 months from the presumed date of HIV-1 infection (ID142) (Extended Data Table 1).

Although there was no difference in time to loss of virologic control between the lefitolimod/placebo group and the placebo/placebo group ( $P = 0.49$ ) (Fig. 2e), loss of virologic control occurred significantly later in both the placebo/bNAb group (median delay, 12.5 weeks,  $P = 0.003$ ) and the lefitolimod/bNAb group (median delay, 9.5 weeks,  $P = 0.004$ ) compared to the placebo/placebo group (Fig. 2f,g). There was no difference in time to loss of virologic control between the placebo/bNAb and lefitolimod/bNAb group ( $P = 0.42$ ) (Fig. 2h). Similar differences were observed when we analyzed time to first plasma HIV-1 RNA measurement  $>50$  or  $>1,000$  copies per milliliter (Extended Data Fig. 2). Of note, the median initial viral doubling time, defined as the trajectory of the increase of the initial slope in plasma HIV-1 RNA during ATI, was slower for the two bNAb groups compared to non-bNAb groups (Fig. 2i). Median initial viral doubling time was significantly slower for the lefitolimod/bNAb group compared to the placebo/placebo ( $P = 0.030$ ) and lefitolimod/placebo ( $P = 0.0026$ ) groups. The median initial viral doubling time strongly correlated with time to loss of virological control ( $P < 0.0001$ ) (Fig. 2j).

In the placebo/bNAb group, two of the four individuals who did not meet criteria for loss of virologic control displayed partial virologic control with viremia ranging from  $<20$  to 70,000 copies per milliliter, whereas the other two individuals maintained complete virologic control with undetectable plasma HIV-1 RNA levels. These two individuals with undetectable viral load elected not to restart ART after the end of the ATI and continue to control under close monitoring 18 months after stopping ART (Extended Data Fig. 3). Collectively, these findings demonstrate that, in a placebo-controlled setting, administration of two bNAbs significantly delayed viral rebound and was associated with partial or complete ART-free virologic control among a subset of individuals. Lefitolimod did not impact the outcome of the ATI.



**Fig. 1 | TITAN trial design (a) and abbreviated CONSORT flow diagram (b).** Solid green arrows indicate lefitolimod injections. Solid red and blue triangles indicate 3BNC117 and 10-1074 infusions, respectively. Empty green arrows as well as red and blue triangles indicate placebo injections or infusions, respectively.

Gray shaded areas indicate time on ART, and white shaded areas indicate still interrupting ART during the 25 weeks of ATI. The analysis section is presented in full in Extended Data Fig. 1. SAE, severe adverse event.

### bNAb sensitivity and serum concentrations

The proviral reservoir’s sensitivity to neutralization by 3BNC117 and 10-1074 was assessed for each potential study participant as part of the inclusion criteria before randomization (see Methods for details). bNAb sensitivity screening was primarily done using the PhenoSense Monoclonal Antibody Assay (LabCorp–Monogram Biosciences). If phenotypic sensitivity results were inconclusive or the PhenoSense assay could not be carried out, single-genome amplification and sequencing of HIV-1 envelope (*env*) followed by genotypic sensitivity prediction was used as an alternate screening method (Fig. 3 and Extended Data Fig. 4). Among participants who received bNAb, plasma HIV *env* sequences were analyzed for known resistance mutations if viral rebound occurred (Fig. 3). As serum levels of 3BNC117 gradually

declined to subtherapeutic levels, most participants in the bNAb groups experienced viral rebound while seemingly on 10-1074 monotherapy (Fig. 4a,b). Post hoc analyses demonstrated that the prevalence of genotypic 10-1074 resistance mutations increased from 13% at screening to 89% at viral rebound among bNAb-treated individuals (Fig. 3). At the time of loss of virologic control, the mean serum concentrations were 13.2 μg ml<sup>-1</sup> (s.d. ± 10.6) for 3BNC117 and 73.3 μg ml<sup>-1</sup> (s.d. ± 47.2) for 10-1074 in the placebo/bNAb group and 20.1 μg ml<sup>-1</sup> (s.d. ± 21.0) and 88.2 μg ml<sup>-1</sup> (s.d. ± 70.1), respectively, for the lefitolimod/bNAb group. Of note, in a mixed-effects model, the decline in serum bNAb concentrations after the second antibody dose was significantly faster in the lefitolimod/bNAb group compared to the placebo/bNAb group ( $P = 0.023$  for 3BNC117 and  $P = 0.019$  for 10-1074) (Fig. 4c,d).

**Table 1 | Baseline characteristics of the study population**

	Placebo/placebo (n=11)	Leflotolimod/placebo (n=11)	Placebo/bNAb (n=12)	Leflotolimod/bNAb (n=12)
Age (years)	54 (45–60)	44 (38–53)	51 (41–54)	48 (31–53)
Female sex	2 (18)	1 (9)	3 (25)	1 (8)
Race and ethnicity				
African European	0 (0)	2 (18)	0 (0)	0 (0)
White	11 (100)	7 (64)	11 (92)	11 (92)
More than one	0 (0)	2 (18)	1 (8)	1 (8)
Time since HIV-1 diagnosis (years)	11 (4–37)	12 (1–15)	11 (2–29)	8 (2–26)
Time from HIV-1 diagnosis to ART (years)	0 (0–14)	1 (0–5)	0 (0–21)	0 (0–7)
Time on ART (years)	8 (4–23)	9 (1–14)	8 (2–23)	8 (2–26)
HIV subtype <sup>a</sup>				
B	8 (73)	5 (45)	9 (75)	11 (92)
Non-B	0 (0)	4 (36)	2 (17)	1 (8)
Not available	3 (27)	2 (18)	1 (8)	0 (0)
CD4 <sup>+</sup> T cell count (cells per mm <sup>3</sup> )	743 (708–820)	694 (620–920)	1,027 (808–1,240)	832 (723–1,450)
HLA class I alleles <sup>a</sup>				
Risk: HLA-B*07 and HLA-B*35	5 (45)	5 (45)	3 (25)	5 (42)
Protective: HLA-B*27, HLA-B*57 and HLA-B*58	1 (9)	2 (18)	2 (17)	0 (0)

Data are n (%) or median (range).<sup>a</sup> Individual HIV-1 subtypes and HLA class I can be found in Supplementary Table 1.

Although their reservoir was predicted to be sensitive based on phenotypic screening, the three bNAb recipients (ID133, ID101 and ID822) with the shortest time to loss of virologic control (<8 weeks) were subsequently shown to harbor genotypic 10-1074-resistant proviruses at enrollment (Fig. 3). Notably, the two individuals with complete virologic control were enrolled based on their genotypic bNAb sensitivity screening, but post hoc phenotypic data indicated some level of resistance to either 3BNC117 or 10-1074 at enrollment. In summary, despite careful screening for bNAb sensitivity before enrollment, some participants appeared to harbor resistant proviruses that resulted in early viral rebound. These observations highlight the challenges with the current approaches to DNA-based bNAb sensitivity screening in PWH on long-term ART.

### Quantification of intact HIV proviruses


We used a digital droplet PCR (ddPCR) assay (Intact Proviral DNA Assay (IPDA)) to estimate the proportion of intact proviruses in CD4<sup>+</sup> T cells. For some (9/31) individuals with subtype B for whom IPDA failed, as well as for the individuals with non-B subtypes ( $n = 6$ ), we used alternative primer/probe or an IPDA-like duplexed ddPCR (3dPCR) assay (Supplementary Table 1) to estimate the intact reservoir<sup>6</sup>. The number of intact proviruses varied among individuals at baseline (range: 1.18–2,576.62 copies per 10<sup>6</sup> CD4<sup>+</sup> T cells; Extended Data Table 1) but did not differ between groups ( $P = 0.50$ ). The mean proportion of intact proviruses at baseline was 7% (Extended Data Fig. 5a). Six weeks after starting ATI, the placebo/placebo and lefotolimod/placebo groups showed significant increases in circulating intact and defective proviruses (Fig. 5a and Extended Data Fig. 5b,c). At this time, 16 of 20 individuals in the placebo/placebo and lefotolimod/placebo groups had reached criteria for loss of virologic control (Fig. 2a,b). The largest median increase in intact and defective proviruses was observed among the lefotolimod/placebo group (Fig. 5b and Extended Data Fig. 5d,e). The median increase in intact proviruses among the placebo/placebo group was significantly higher than the median changes in the two bNAb groups (Fig. 5b). Similar changes were observed for defective proviruses (Extended Data Fig. 5d,e). In contrast, we found no significant increases in intact or

defective proviruses in the bNAb recipients over the same time period, suggesting that the two bNAb restricted HIV-1 replication during ATI. In summary, we observed that the frequency of CD4<sup>+</sup> T cells harboring intact proviruses expanded after ATI in non-bNAb recipients but that bNAb administration prevented reservoir expansion during the early phase of the ATI.

### HIV-1-specific T cell immunity


The median frequency of HIV-1-specific CD8<sup>+</sup> T cells increased from pre-ATI to week 6 in all four treatment groups as measured by the activation-induced marker (AIM) assay, but the increase was significant only for the lefotolimod/placebo group (Fig. 5c). This change in HIV-1-specific CD8<sup>+</sup> T cell responses from pre-ATI to week 6 was significantly correlated with measurable plasma HIV-1 RNA at week 6 ( $r = 0.51$ ,  $P = 0.021$ ) (Extended Data Fig. 6a). The frequency of HIV-1-specific CD8<sup>+</sup> T cells also increased significantly from the pre-ATI timepoint to week 13 for the lefotolimod/bNAb group ( $P = 0.0059$ ). To disentangle increased antigen exposure from a bNAb-mediated vaccinal effect as potential cause of increased HIV-1 specific immunity, we separated bNAb-treated individuals in a post hoc analysis into two groups based on whether their plasma HIV-1 RNA was below or above 50 copies per milliliter during the ATI. As expected, bNAb-treated individuals with plasma HIV-1 RNA above 50 copies per milliliter had higher HIV-1-specific CD8<sup>+</sup> T cell responses at week 13 compared to pre-ATI ( $P = 0.0052$ ) (Fig. 5d). We also observed a non-significant increase in total HIV-1-specific CD8<sup>+</sup> T cell responses among bNAb-treated individuals whose plasma HIV-1 RNA was below 50 copies per milliliter at week 13 ( $P = 0.094$ ) (Fig. 5d), but we found no detectable changes in Gag-specific CD8<sup>+</sup> T cell responses or in Gag-induced interferon (IFN)- $\gamma$  or granzyme B (GzmB) responses (Extended Data Fig. 6b–d). The frequency of HIV-1-specific CD4<sup>+</sup> T cells remained relatively stable over time in all four groups (Extended Data Fig. 6e). Thus, whereas HIV-1-specific CD8<sup>+</sup> T cell responses increased with increasing plasma HIV-1 RNA during the ATI, bNAb recipients who maintained plasma HIV-1 RNA <50 copies per milliliter during 3 months of ATI did not experience substantial increases in their HIV-1-specific CD8<sup>+</sup> T cell responses that would be suggestive of a bNAb-mediated





**Fig. 2 | Viral kinetics and time to loss of virologic control during 25 weeks of ATI.** **a–d**, Individual plasma HIV-1 RNA levels are shown in the four randomization groups during 25 weeks of ATI: **a**, placebo/placebo group ( $n = 10$ ); **b**, lefitolimod/placebo ( $n = 10$ ); **c**, placebo/bNAb ( $n = 11$ ); and **d**, lefitolimod/bNAb ( $n = 12$ ). Solid green arrows indicate lefitolimod injections. Solid red and blue triangles indicate 3BNC117 and 10-1074 infusions, respectively. Empty green arrows as well as red and blue triangles indicate placebo injections or infusions, respectively. Light gray shaded areas indicate time on ART, and white shaded areas indicate still interrupting ART during the 25 weeks of ATI. The three horizontal dotted lines indicate plasma HIV-1 RNA limit of quantification and 1,000 and 100,000 copies per milliliter, respectively. Viral rebound was defined as 4 weeks with plasma HIV-1 RNA >1,000 copies per milliliter or two consecutive measurements >100,000 copies per milliliter. **e–h**, Kaplan–Meier curves showing the percentage of individuals still interrupting ART during the 25 weeks of ATI. Time

to loss of virologic control for the three active interventional groups compared to the placebo/placebo group: lefitolimod/placebo (**e**), placebo/bNAb (**f**) and lefitolimod/bNAb (**g**). **h**, Time to loss of virologic control for the placebo/bNAb group compared to the lefitolimod/bNAb group. *P* values were calculated using the log-rank test. **i**, Dot plot of the initial viral doubling time in plasma HIV-1 RNA during ATI among the four randomization groups. The number of individuals per group is as stated for **a–d**, but the two individuals with completed virologic control in the placebo/bNAb group were given a high doubling time of 100 d beyond the axis to be included and to avoid skewing the data (lines at median and IQRs). *P* values comparing between groups were calculated using the two-tailed Mann–Whitney test. **j**, Correlation between time to loss of ART-free virologic control during the 25 weeks of ATI and initial viral doubling time among the four randomization groups. The number of individuals per group is as stated in **i**. *P* value was calculated using two-tailed Spearman’s correlation coefficient.



**Fig. 3 | bNAb sensitivity at screening and viral rebound.** bNAb sensitivity was primarily analyzed using the PhenoSense Monoclonal Antibody Assay with predefined IC<sub>90</sub> thresholds for 3BNC117 (<1.5 µg ml<sup>-1</sup>) and 10-1074 (<2.0 µg ml<sup>-1</sup>) and MPI ≥98%. In six participants, the PhenoSense Assay failed, and we secondarily used proviral HIV-1 *env* sequences on a genotypic prediction algorithm with predefined thresholds of >90% known sequences are sensitive. One participant (ID142) was enrolled based upon the genotypically analysis, but post hoc phenotypic data showed an IC<sub>90</sub> of 1.8 µg ml<sup>-1</sup> for 3BNC117. In another participant (ID314), both the PhenoSense Assay and *env* sequencing initially failed, and we tertiary (Methods) included this individual based on the assumption that both assays failed due to a very small reservoir size, but post hoc phenotypic data showed archived 10-1074-resistant proviruses. For individuals

enrolled based upon the phenotypic data, genotypical data were subsequently obtained except for one participant (ID314). If the participants had reached criteria for viral rebound before or were viremic at the end of the 25 weeks of ATI, bNAb sensitivity using plasma HIV-1 *env* sequences was analyzed using the same genotypic prediction algorithm. ID412 did not have samples available at viral rebound, and *env* sequencing failed for ID601. ID314 and ID142 had complete virologic control at the end of the 25 weeks of ATI. Solid red and blue triangles indicate 3BNC117 and 10-1074 infusions, respectively. Light gray shaded areas indicate time on ART, and white shaded boxes indicate still interrupting ART during the 25 weeks of ATI. Dark gray boxes are assay failures; orange boxes are no samples available; and dark blue boxes are no viremia at the end of 25-week ATI.

vaccinal effect or low-level antigen exposure during bNAb-mediated viral suppression.

**Safety**

Both lefitolimod and bNAb were overall safe. A total of 253 adverse events (AEs) were registered, of which 94 were determined to be unrelated to any investigational drug, including placebo (Extended Data Tables 2 and 3). Of 81 AEs considered related to lefitolimod, 75 were

graded mild and six were graded moderate, with the most common AEs being injection site reaction (*n* = 39) and fatigue (*n* = 6). Of 14 AEs considered related to bNAb, 11 were graded mild, two were graded moderate and one was graded severe, with fatigue (*n* = 5) being the most commonly reported AE. An infusion-related reaction categorized as severe and related to the second 3BNC117 infusion (ID133) resolved with fluid therapy, antihistamine and corticosteroid without any sequelae. Another AE, not related to study drugs, was categorized

as severe, where a participant (ID813) had a vasovagal reaction just after insertion of the intravenous needle before bNAb infusion. The reaction resolved with fluid therapy without any sequelae. Median CD4<sup>+</sup> T cell counts decreased from study start to end of study in three of the four groups (Extended Data Fig. 7) but was stable in the placebo/bNAb group. Among participants who re-initiated ART after viral rebound, all but one (ID807) achieved viral re-suppression after a median of 71 d (IQR: 38–116), and median CD4<sup>+</sup> T cell counts had recovered to pre-ATI levels in all four groups (Extended Data Fig. 7b).

## Discussion

In this randomized, placebo-controlled HIV-1 cure trial among PWH on long-term ART who screened sensitive to the study bNAbs, we found that two doses of 3BNC117 and 10-1074 in the setting of ATI led to a significant delay in viral rebound compared to placebo. We also observed that 36% of individuals in the placebo/bNAb group compared to none in the placebo group maintained partial or complete virologic control at the end of the 25-week ATI. There were no differences in time to viral rebound or change in reservoir size between the placebo/placebo and the lefitolimod/placebo group or between the placebo/bNAb and lefitolimod/bNAb group. Thus, although there was no added clinical or immunological benefit of combining lefitolimod with bNAbs, antibody treatment alone led to a significant delay in viral rebound, and some bNAb-treated individuals experienced long-term ART-free virologic control.

Single-arm trials show that bNAb-sensitive PWH on long-term ART receiving 3–8 infusions of 3BNC117 and 10-1074 maintain prolonged viral suppression in the absence of ART<sup>27–29</sup>. Notably, our study was not designed to evaluate the ability of bNAbs to replace ART as a means to durably suppress viral replication but, rather, to address an important HIV-1 cure hypothesis: could a TLR9 agonist alone or in combination with bNAbs increase the chance of long-term ART-free control? We addressed this question using the most rigorous study design: a factorial, randomized, placebo-controlled, double-blinded trial. We administered bNAbs only twice—one infusion before stopping ART and a second infusion 3 weeks after ATI—but found that time to viral rebound after the last infusion was similar to that seen in previous multi-dose trials<sup>27–29</sup>.

Of note, we administered 10-1074 at 20 mg kg<sup>-1</sup> compared to 30 mg kg<sup>-1</sup> for 3BNC117 to compensate for the longer half-life of 10-1074 compared to 3BNC117, but, despite differential dosing, 3BNC117 was cleared from plasma faster than 10-1074, leading to a period of effective monotherapy with the latter. Consistent with the pharmacokinetics, 89% of our participants developed new 10-1074 resistance mutations at viral rebound indicative of residual 10-1074 monotherapy, which has also been reported in other trials. Collectively, these studies demonstrate that 10-1074 monotherapy is not sufficient to maintain virologic suppression<sup>34</sup>.

In our study, 18% of participants (2/11) in the placebo/bNAb group maintained complete virologic control (HIV RNA <20 copies per milliliter) throughout the 25-week ATI, and both elected to continue off ART after the ATI ended. In previous trials using the same bNAb combination, 0% (0/7)<sup>28</sup>, 11% (1/9)<sup>27</sup> and 17% (2/12)<sup>29</sup> of bNAb-sensitive individuals maintained complete virologic control during ATI. Furthermore, in

our study, bNAb treatment changed the trajectory of viral rebound as evidenced by slower plasma virus doubling time during the ATI, which is suggestive of stronger immune pressure against the replicating virus in bNAb recipients.

Although virologic or immunological features characteristic of post-bNAb controllers have yet to be identified, pre-ATI HIV-1 reservoir size was seven-fold lower in post-ART controllers compared to non-controllers in a cohort study<sup>35</sup>. Further analysis showed that the reservoir in post-treatment controllers remained stable during ATI<sup>36</sup>. We found that the frequency of intact HIV-1 in CD4<sup>+</sup> T cells remained stable during bNAb-mediated suppression of plasma viral load but expanded upon loss of virologic control. The two individuals who maintained complete virologic control maintained a stable reservoir throughout the ATI.

As expected, we found that HIV-1-specific CD8<sup>+</sup> T cell responses increased during viral rebound. We also observed a modest increase in HIV-1-specific CD8<sup>+</sup> T cell responses among bNAb recipients who maintained viral suppression, but, in contrast to a previous report<sup>37</sup>, we observed no change in Gag-specific CD8<sup>+</sup> T cell responses or Gag-induced cytokine release. Thus, there was no clear indication of a vaccinal effect<sup>31,37–42</sup> in the present study. The failure to broadly stimulate cellular immunity could be due to low amounts of antigen at the time of bNAb administration because bNAb dosed at ART initiation among newly diagnosed viremic individuals induced sustained strong HIV-1-specific CD8<sup>+</sup> T cell responses<sup>6,30</sup>. Potent HIV-1-specific CD8<sup>+</sup> T cell immunity is critical for maintaining virologic suppression in humans and bNAb-treated macaques<sup>31,32,43</sup>. Whether increases in HIV-1-specific cellular immunity after bNAb administration contributed to virologic control in the present study is unclear, but it seems plausible that a combined restriction of outgrowth from the viral reservoir, along with potent cellular responses, contributed to long-term ART-free control in some individuals.

The combination of 3BNC117 and 10-1074 neutralizes a broad range of HIV-1 subtypes *ex vivo*<sup>44</sup>, but bNAb treatment is still challenged by archived resistant mutations<sup>29,45</sup>. To address this issue, we pre-screened all participants for bNAb sensitivity using both genotypic and phenotypic approaches. However, neither bNAb sensitivity analysis accurately predicted time to viral rebound, adding further evidence of the challenge of effective screening for bNAb sensitivity. This finding is in line with other recent studies, which indicate that currently available bNAb sensitivity testing of the proviral reservoir does not accurately predict the clinical outcome of bNAb treatment<sup>6,29</sup>. Of note, the average serum concentrations of 3BNC117 at viral rebound were slightly higher than previously reported, where viral rebound generally occurred after 3BNC117 decreased below 10 µg ml<sup>-1</sup> (refs. 27,29). However, both studies were relatively small, and serum antibody concentrations were measured by different methods.

Lefitolimod alone or in combination with bNAbs did not significantly impact time to viral rebound or any of the immunological or virologic outcomes in this trial. Unexpectedly, co-administration of lefitolimod led to a faster decline in bNAb serum concentrations<sup>24,25</sup>. Lefitolimod administration has been shown to increase proportions of CD16<sup>+</sup> NK cells among PWH<sup>12–14</sup>, which theoretically could facilitate increased binding and faster clearance of bNAbs. Of note, a faster

### Fig. 4 | Plasma HIV-1 RNA and bNAb serum levels for the two bNAb groups.


**a, b**, Plasma HIV-1 RNA (solid black dot with line; left y axis) and bNAb serum concentrations (3BNC117, solid red square with line; 10-1074, solid blue triangle with line; right y axis) for the placebo/bNAb group (**a**) and lefitolimod/bNAb group (**b**) during 25 weeks of ATI. Solid green arrows indicate lefitolimod injections. Solid red and blue triangles indicate 3BNC117 and 10-1074 infusions, respectively. Empty green arrows as well as red and blue triangles indicate placebo injections or infusions, respectively. Gray shaded areas indicate time on ART, and white shaded areas indicate still interrupting ART during the 25 weeks of ATI. The lower limit of quantification of plasma HIV-1 RNA was 20

copies per milliliter. In the placebo/bNAb group, serum concentration is shown for 10 individuals; ID601 did not have serum samples taken; and ID133 received only the first bNAb infusions due to a severe adverse event. In the lefitolimod/bNAb groups, serum concentration is shown for all individuals (*n* = 11) except ID609, who did not have serum samples taken. **c, d**, Group levels of bNAb serum concentrations for the placebo/bNAb group (*n* = 10) (**c**) and lefitolimod/bNAb group (*n* = 11) (**d**) during 25 weeks of ATI. Mixed-effect modeling with open squares and triangles with lines for mean (s.d.) 3BNC117 and 10-1074 serum concentrations, respectively, during 25 weeks of ATI.


decline in serum concentration of an Fc-modified version of PGT121, a bNAb with similar properties to 10-1074, was also observed when it was co-administered with a TLR7 agonist in NHPs<sup>26</sup>. Anti-drug antibodies (ADAs) against anti-HIV-1 bNAbs rarely develop in humans, and, when

they do, the presence of ADA has discernible impact on bNAb elimination kinetics<sup>44</sup>.

The combination of a TLR7 agonist and PGT121 was shown to induce long-term ART-free virologic control among 34–45% of







**Fig. 5 | Size of the intact HIV-1 reservoir and HIV-1-specific CD8<sup>+</sup> T cell immunity.** **a**, Dot plot of the size of the intact HIV-1 reservoir at ATI start (day 0) and after 6, 13 and 25 weeks of ATI among individuals in the four randomization groups (lines at median and IQRs): placebo/placebo ( $n = 10$ ); lefitolimod/placebo ( $n = 9$ ); placebo/bNAb ( $n = 10$ ); and lefitolimod/bNAb ( $n = 11$ ). All weeks are shown, including weeks with no data available.  $P$  values comparing within groups were calculated using the paired two-tailed Wilcoxon test. Only  $P$  values below 0.05 are shown. **b**, Median change in the intact HIV-1 reservoir between week 6 of the ATI and pre-ATI for the four randomization groups are shown. Data are median and IQRs with the placebo/placebo group as the reference. Placebo/placebo group ( $n = 10$ ); lefitolimod/placebo ( $n = 8$ ); placebo/bNAb ( $n = 9$ ); and lefitolimod/bNAb ( $n = 9$ ).  $P$  values comparing between groups were calculated using the two-tailed Mann-Whitney test. **c**, Dot plot of the frequency of HIV-1-specific CD8<sup>+</sup> T cells at ATI start (day 0) and after 6, 13 and 25 weeks of ATI

among individuals in the four randomization groups (lines at median and IQRs): placebo/placebo ( $n = 10$ ); lefitolimod/placebo ( $n = 9$ ); placebo/bNAb ( $n = 11$ ); and lefitolimod/bNAb ( $n = 12$ ). All weeks are shown, including weeks with no data available.  $P$  values comparing within groups and between groups were calculated using the paired two-tailed Wilcoxon test and two-tailed Mann-Whitney test, respectively. Only  $P$  values below 0.05 are shown. **d**, Dot plot of median fold change in HIV-1-specific CD8<sup>+</sup> T cells after 13 weeks of ATI among individuals with either plasma HIV-1 RNA below (left) or above (right) 50 copies per milliliter in the two randomization groups receiving bNAb combination (lines at median and IQRs). Plasma HIV-1 RNA below 50 copies per milliliter: placebo/bNAb ( $n = 5$ ) and lefitolimod/bNAb ( $n = 1$ ); plasma HIV-1 RNA above 50 copies per milliliter: placebo/bNAb ( $n = 5$ ) and lefitolimod/bNAb ( $n = 9$ ).  $P$  values comparing within groups were calculated using the paired two-tailed Wilcoxon test.

NHPs<sup>24,46</sup>, so why did a TLR9 agonist in combination with two bNABs fail to produce similar effects in humans? Potential explanations include the lower degree of fitness and greater bNAB sensitivity of simian-human immunodeficiency virus (SHIV) versus HIV-1, a smaller reservoir in macaques and very early ART initiation (day 7 or day 9 after infection) in the NHP model. In contrast, our study population consisted mainly of people who started ART during the chronic phase of infection and had large genetically diverse reservoirs with varying degrees of bNAB sensitivity. Early ART initiation and bNAB sensitivity are two key parameters that determine the outcome of ATIs in bNAB studies in humans and NHPs. In two complementary studies with NHPs that started ART later (day 14 and day 365 after infection), the combination of TLR7 agonist and one or more bNABs tended to be associated with a lower frequency of post-intervention control (0%, 22% and 50%) than in the studies where animals started ART at day 7 or day 9 after infection<sup>25,26</sup>.

Another potential explanation is differences in immune signaling between TLR7, which recognizes viral single-stranded RNA, and TLR9, which recognizes unmethylated DNA with CpG motifs<sup>10</sup>. Although both TLR7 and TLR9 are expressed in the endosomal compartment and signal via myeloid differentiation factor 88 (MyD88), there are notable differences<sup>10</sup>. In human peripheral blood mononuclear cells (PBMCs), TLR7 agonists induce a rapid burst of type I IFN transcripts, whereas TLR9 agonists trigger a slower but sustained expression of type I IFN<sup>47</sup>. The subtypes of induced type I IFNs also differ between the two agonists. Collectively, these experimental and biological differences may explain the divergent results between macaque and human HIV-1 cure trials.

Despite lefitolimod's well-documented ability to enhance DC-mediated cross-presentation, upregulate IFN-stimulated genes and activate multiple innate and adaptive immune cell subsets<sup>12-15</sup>, we

observed no discernible impact of TLR9 agonist treatment on T cell immunity. Our findings may indicate that such immunostimulatory molecules may not effectively boost HIV-1-specific immunity unless substantial amounts of HIV-1 antigen are concurrently present in the same anatomical location. This hypothesis gains support from recent discoveries in cancer research, wherein intra-tumoral injection of cytokines or TLR9 agonists has demonstrated substantially greater effects on tumor size and tumor-specific immune responses compared to the same therapies administered s.c. or i.v.<sup>48,49</sup>. However, ongoing trials will yield additional insights into the potential of an HIV-1 cure strategy that centers on the combination of bNAbs with immunostimulatory agents, such as other TLR agonists, pegylated interferon- $\alpha$ 2b or IL-15 super-agonists. These trials will determine whether this approach can induce post-treatment control or if it necessitates a re-evaluation of our current strategy.

The reported results have limitations and may not be generalizable to all PWH. Specifically, our ability to predict proviral bNAb sensitivity based on the PhenoSense assay or sequence analysis is limited. Undetected bNAb resistance leading to treatment failure may have clinical implications, particularly if bNAbs were to replace modern ART regimens as suppressive antiviral treatment or if used in combination with the new long-acting small-molecule-based injectable antivirals. Most enrolled participants were male. In contrast to some bNAb trials<sup>28</sup>, we did not exclude individuals who initiated ART during the chronic phase of infection. Although this inclusive approach made our study population more representative of the overall population, it might also have contributed to raising the bar for success, as PWH who started ART during the acute/early phase of infection harbor smaller and less diverse HIV-1 reservoirs and may be more likely to become post-treatment controllers<sup>50–52</sup>.

Although lefitolimod and bNAbs were overall safe, the CD4<sup>+</sup> T cell count dropped in response to recrudescence viremia. Reassuringly, once plasma HIV-1 RNA was re-suppressed, the CD4<sup>+</sup> T cell counts returned to pre-ATI levels. We also found that the size of the HIV-1 reservoir expanded at rebound. In a previous study<sup>53</sup>, 22 PWH interrupted ART for a median of 4 months and were followed for ~2 years after restarting ART. The investigators found no difference in HIV-1 reservoir size from pre-ATI and until the last follow-up timepoint. Thus, although viral rebound might cause transient CD4<sup>+</sup> cell count declines and HIV-1 reservoir size increases, the long-term clinical implications of these changes, if any, appear to be limited. Of note, one individual in this study (ID807) did not achieve rapid viral re-suppression despite having therapeutic ART drug concentrations and no evidence of emerging or archived resistance mutations. We speculate that this case of slow viral resuppression could be due to clonally expanded defective proviruses, which were recently reported to be a potential source of non-suppressible viremia among fully ART-adherent individuals<sup>54</sup>.

In conclusion, although there was no added benefit of combining a TLR9 agonist with bNAbs compared to bNAbs alone, this was, to our knowledge, the first placebo-controlled, double-blinded trial to show prolonged ART-free virologic control during ATI in individuals receiving just two doses of bNAbs. This finding provides further support for investigating bNAbs as a component in long-acting treatment and HIV-1 curative strategies. However, additional interventions, optimization of bNAbs and bNAb drug combinations<sup>55,56</sup> and/or administration of bNAbs in the setting of higher antigen load will likely be needed to achieve ART-free HIV-1 remission in the majority of PWH on long-term suppressive ART.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02547-6>.

## References





















- Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13–e21 (2014).
- Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. *AIDS* **30**, 343–353 (2015).
- Kroon, E. D. M. B. et al. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. *J. Virus Erad.* **6**, 100004 (2020).
- Leth, S. et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. *Lancet HIV* **3**, e463–e472 (2016).
- Gruell, H. et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. *Lancet Microbe* **3**, e203–e214 (2022).
- Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. *Nat. Med.* **28**, 2424–2435 (2022).
- Miller, J. S. et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. *Nat. Med.* **28**, 392–400 (2022).
- Levy, Y. et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. *J. Clin. Invest.* **119**, 997–1007 (2009).
- Kapp, K., Kleuss, C., Schroff, M. & Wittig, U. Genuine immunomodulation with dSLIM. *Mol. Ther. Nucleic Acids* **3**, e170 (2014).
- Martinsen, J. T., Gunst, J. D., Højen, J. F., Tolstrup, M. & Søggaard, O. S. The use of Toll-like receptor agonists in HIV-1 cure strategies. *Front. Immunol.* **11**, 1112 (2020).
- Damiano, V. et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. *Proc. Natl Acad. Sci. USA* **104**, 12468–12473 (2007).
- Vibholm, L. et al. Short-course Toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. *Clin. Infect. Dis.* **64**, 1686–1695 (2017).
- Vibholm, L. K. et al. Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1<sup>+</sup> individuals. *AIDS* **33**, 1315–1325 (2019).
- Schleimann, M. H. et al. TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. *EBioMedicine* **45**, 328–340 (2019).
- Krurup, A. R. et al. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. *Mucosal Immunol.* **11**, 449–461 (2018).
- Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. *Nature* **517**, 381–385 (2015).
- Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. *Immunity* **36**, 491–501 (2012).
- Altfeld, M. & Gale, M. Jr Innate immunity against HIV-1 infection. *Nat. Immunol.* **16**, 554–562 (2015).
- Carrington, M. & Alter, G. Innate immune control of HIV. *Cold Spring Harb. Perspect. Med.* **2**, a007070 (2012).
- Buzon, M. J. et al. Susceptibility to CD8 T cell-mediated killing influences the reservoir of latently HIV-1 infected CD4 T cells. *J. Acquir. Immune Defic. Syndr.* **65**, 1–9 (2013).
- Offersen, R. et al. A novel Toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4<sup>+</sup> T cells. *J. Virol.* **90**, 4441–4453 (2016).

22. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* **333**, 1633–1637 (2011).
23. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proc. Natl Acad. Sci. USA* **109**, E3268–E3277 (2012).
24. Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. *Nature* **563**, 360–364 (2018).
25. Hsu, D. C. et al. TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. *PLoS Pathog.* **17**, e1009339 (2021).
26. Moldt, B. et al. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. *PLoS Pathog.* **18**, e1010467 (2022).
27. Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature* **561**, 479–484 (2018).
28. Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. *Nature* **606**, 375–381 (2022).
29. Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. *Nature* **606**, 368–374 (2022).
30. Rosás-Umbert, M. et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunity. *Nat. Commun.* **13**, 6473 (2022).
31. Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. *Nature* **543**, 559–563 (2017).
32. Nishimura, Y. et al. Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. *J. Exp. Med.* **218**, e20201214 (2021).
33. Gunst, J. D., Højen, J. F. & Søgaard, O. S. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission. *Curr. Opin. HIV AIDS* **15**, 309–315 (2020).
34. Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nat. Med.* **23**, 185–191 (2017).
35. Sharaf, R. et al. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. *J. Clin. Invest.* **128**, 4074–4085 (2018).
36. Etemad, B. et al. HIV post-treatment controllers have distinct immunological and virological features. *Proc. Natl Acad. Sci. USA* **120**, 2017 (2023).
37. Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. *Nat. Med.* **26**, 222–227 (2020).
38. Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. *Nat. Med.* **25**, 547–553 (2019).
39. Lu, C.-L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. *Science* **352**, 1001–1004 (2016).
40. Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. *Science* **352**, 997–1001 (2016).
41. Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. *Nature* **535**, 556–560 (2016).
42. DiLillo, D. J. & Ravetch, J. V. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. *Cell* **161**, 1035–1045 (2015).
43. Betts, M. R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8<sup>+</sup> T cells. *Blood* **107**, 4781–4789 (2006).
44. Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. *PLoS ONE* **14**, e0219142 (2019).
45. Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N. Engl. J. Med.* **375**, 2037–2050 (2016).
46. Walker-Sperling, V. E. K. et al. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. *Nat. Commun.* **13**, 3463 (2022).
47. Puig, M. et al. TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. *J. Leukoc. Biol.* **91**, 147–158 (2011).
48. Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. *Ann. Oncol.* **28**, xii33–xii43 (2017).
49. Dongye, Z., Li, J. & Wu, Y. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. *Br. J. Cancer* **127**, 1584–1594 (2022).
50. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. *PLoS Pathog.* **9**, e1003211 (2013).
51. Namazi, G. et al. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. *J. Infect. Dis.* **218**, 1954–1963 (2018).
52. Rasmussen, T. A. et al. Antiretroviral initiation at  $\geq 800$  CD4<sup>+</sup> cells/mm<sup>3</sup> associated with lower human immunodeficiency virus reservoir size. *Clin. Infect. Dis.* **75**, 1781–1791 (2022).
53. Huiting, E. D. et al. Impact of treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who initiated antiretroviral therapy during the early phase of infection. *J. Infect. Dis.* **220**, 270–274 (2019).
54. White, J. A. et al. Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia. *J. Clin. Invest.* **133**, e165245 (2023).
55. Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. *Nat. Med.* **28**, 1288–1296 (2022).
56. Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. *Proc. Natl Acad. Sci. USA* **110**, 16538–16543 (2013).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Jesper D. Gunst <sup>1,2,21</sup>, Jesper F. Højten <sup>1,2,21</sup>, Marie H. Pahun <sup>1,2,21</sup>, Miriam Rosás-Umbert <sup>1,2,21</sup>, Birgitte Stiksrud<sup>3</sup>, James H. McMahon <sup>4</sup>, Paul W. Denton <sup>5</sup>, Henrik Nielsen<sup>6,7</sup>, Isik S. Johansen <sup>8</sup>, Thomas Benfield<sup>9,10</sup>, Steffen Leth <sup>1,11</sup>, Jan Gerstoft<sup>10,12</sup>, Lars Østergaard<sup>1,2</sup>, Mariane H. Schleimann <sup>1,2</sup>, Rikke Olesen<sup>1,2</sup>, Henrik Støvring<sup>13</sup>, Line Vibholm <sup>1,2</sup>, Nina Weis <sup>9,10</sup>, Anne M. Dyrhol-Riise <sup>3,14</sup>, Karen B. H. Pedersen<sup>10</sup>, Jillian S. Y. Lau<sup>4,15,16</sup>, Dennis C. Copertino Jr <sup>17,18</sup>, Noemi Linden <sup>17,18</sup>, Tan T. Huynh<sup>17,18</sup>, Victor Ramos<sup>19</sup>, R. Brad Jones <sup>17,18</sup>, Sharon R. Lewin <sup>4,15,16</sup>, Martin Tolstrup<sup>1,2</sup>, Thomas A. Rasmussen<sup>1,2,15</sup>, Michel C. Nussenzweig <sup>19,20</sup>, Marina Caskey<sup>19</sup>, Dag Henrik Reikvam <sup>3,14</sup> & Ole S. Søgaard <sup>1,2</sup> 

<sup>1</sup>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. <sup>2</sup>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

<sup>3</sup>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway. <sup>4</sup>Department of Infectious Diseases, Alfred Hospital, Melbourne, VIC, Australia. <sup>5</sup>Department of Biology, University of Nebraska at Omaha, Omaha, NE, USA. <sup>6</sup>Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark. <sup>7</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. <sup>8</sup>Department of Infectious Diseases, Odense University Hospital, University of Southern Denmark, Odense, Denmark. <sup>9</sup>Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. <sup>10</sup>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. <sup>11</sup>Department of Internal Medicine, Gødstrup Hospital, Gødstrup, Denmark. <sup>12</sup>Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.

<sup>13</sup>Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.

<sup>14</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway. <sup>15</sup>Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. <sup>16</sup>Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. <sup>17</sup>Infectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. <sup>18</sup>Department of Microbiology and Immunology, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. <sup>19</sup>Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. <sup>20</sup>Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. <sup>21</sup>These authors contributed equally: Jesper D. Gunst, Jesper F. Højten, Marie H. Pahun, Miriam Rosás-Umbert. ✉ e-mail: [olesoega@rm.dk](mailto:olesoega@rm.dk)



## Methods

### Study design

This was a phase 2a, investigator-initiated, randomized, placebo-controlled, double-blinded international multicenter trial enrolling at six sites in Denmark (Aalborg, Aarhus, Gødstrup, Hvidovre, Odense and Rigshospitalet); one site in Oslo, Norway; and one site in Melbourne, Australia (EudraCT: 2018-001165-16). The first participants were enrolled on 16 May 2019. Before any study-related procedures, written informed consent was obtained from the participants. Participants were randomized into one of four groups— placebo/placebo, lefitolimod/placebo, placebo/bNAb or lefitolimod/bNAb—in a 1:1:1:1 ratio (Fig. 1a,b). Sex of participants was determined based on self-reporting. The planned sample size was 48 participants. Study procedures were unfortunately severely impacted by the coronavirus disease 2019 (COVID-19) pandemic, and enrollment had to be paused for longer periods in 2020 and 2021. Due to expiration dates of the study drugs, enrollment closed on 5 November 2021 with 46 of the 48 planned participants enrolled. Screening took place 2–20 weeks before entering the trial. Study participants remained on ART for the first 2 weeks (week –2 to week 0) of the 8-week interventional period. The 25-week ATI started at week 0; thus, administration of study medication ended in week 5 of the ATI. Regular follow-up visits continued for 20 weeks (weeks 6–25) after the last dose of the study medication. Participants who resumed ART during ATI were followed at 4-week intervals until plasma HIV-1 RNA was <50 copies per milliliter. The study was conducted in accordance with Good Clinical Practice and is reported in accordance with the CONSORT 2010 statement<sup>57</sup>. The protocol was approved by the Danish Medicine Authorities (2018092874) and the Norwegian Medicines Agency (20/16305-25) as well as the National Committee on Health Research Ethics in Denmark (1-10-72-292-18), the Regional Committee on Medical and Health Research Ethics in Norway (184485) and the Alfred Human Research Ethics Committee in Australia (project 258/20). Study data were collected and managed in Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Clinical Trial Unit, Department of Clinical Medicine, Aarhus University in Aarhus, Denmark<sup>58,59</sup>. The study was monitored by the Danish Good Clinical Practice Units (<https://gcp-enhed.dk/english/>) in Denmark and Australia and by the Section for Monitoring, Clinical Trial Unit, Oslo (<https://www.ous-research.no/ctu/>) in Norway from screening to the final visit.

### Participants

PWH were aged 18–65 years and on ART for at least 18 months, with plasma HIV-1 RNA <50 copies per milliliter for at least 15 months and a CD4 T cell count >500 cells per mm<sup>3</sup>. Detailed inclusion/exclusion criteria can be found in the study protocol: TITAN-001, version 3.0, 2 July 2021 (Supplementary Information). Participants were reimbursed for transport expenses relating to the study and compensation for lost earnings during study visits but otherwise did not receive any financial compensation for participating in the study.

The sample size calculation was based on the primary endpoint: time to viral rebound during ATI. Time from stopping ART to loss of virological control was compared in the four randomization groups. If loss of virological control occurred, the date of the last measurement of plasma HIV-1 RNA  $\geq 1,000$  copies per milliliter or confirmed >100,000 copies per milliliter was defined as 'date of viral rebound'. Using a two-sample comparison of means with an s.d. of 11 d<sup>1,4</sup>, 10 evaluable participants in each of the two groups would have 90% power to detect a  $\geq 16$ -d difference in time to viral rebound at a 5% significance level. To accommodate for dropouts, we aimed for 12 participants in each group. We considered a two-sided  $\alpha$  value of less than 0.05 to be significant, with no adjustments made for multiple comparisons. We used the IPDA and d3PCR assays as our primary reservoir measurement, as intact proviral DNA is superior to total HIV-1 DNA in terms of estimating the intact HIV-1 reservoir<sup>6</sup>. Protocol amendments did not affect the analysis plan besides the reservoir size analyses described above.

### Randomization

The Clinical Trial Unit at Aarhus University generated the randomization sequence using permuted blocks of four or eight by computer-generated random numbers without stratification to sex and age. Randomization assignment was provided to each site using REDCap.

### Blinding

Participants, study physicians and nurses handling administrations of the study drugs, as well as those individuals doing the analyses, were blinded to interventions. Only the pharmacy and study personnel preparing the study drugs were unblinded to interventions.

The placebo for lefitolimod, 3BNC117 and 10-1074 was sterile physiological saline. Lefitolimod or placebo for lefitolimod was provided to the study physicians and nurses handling the injections as 4 × 2-ml syringes. Placebo for 3BNC117 and 10-1074 or the bNAbs was administered by the study physicians and nurses handling the infusions as 250-ml piggy bags. Labeling contained only information of the study visit and an expiration date and time irrespective of either placebo or study drug.

### Procedures

Lefitolimod or placebo was administered s.c. at a dose of 120 mg once weekly for the first 8 weeks from week –2 to week 5. Lefitolimod dosing was based on previously observed effects in clinical trials<sup>12,13</sup>. 3BNC117 (30 mg kg<sup>-1</sup>) and 10-1074 (20 mg kg<sup>-1</sup>) were sequentially administered as i.v. infusions over 60 min at weeks 0 and 3. The dosing of bNAbs was based on previously observed antiviral efficacy in clinical studies<sup>27–29,34,44,60,61</sup>. The infusions were performed in the Clinical Research Units at Aarhus University Hospital, Copenhagen University Hospital–Hvidovre or Rigshospitalet in Denmark; at the Clinical Research Section at the Department of Infectious Diseases, Oslo University Hospital in Norway; and in the Medical Day Unit at the Alfred Hospital, in Melbourne, Australia. Follow-up visits were conducted at the respective outpatient clinics of participating hospitals. End of study was defined as the timepoint for reaching criteria for viral rebound or week 25, whichever came first. Blood samples were collected at weeks –2, –1, 0, 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 after ATI depending on when the participants reached criteria for viral rebound. Blood samples were processed within 4 h of collection, and serum and plasma samples were stored at –80 °C. PBMCs were isolated by density gradient centrifugation and cryopreserved (–150 °C) in FBS with 10% DMSO. Clinical safety assessments included directed physical examinations and vital sign measurement if indicated and review of AEs and concomitant medications at every visit and reported until the end of study (Fig. 1a). The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale was used to grade AEs. A safety monitoring committee was established to monitor the blinded safety data of the trial. Safety biochemistry was taken at weeks –2, 0, 3, 6, 9, 13 and 25 after ATI. CD4<sup>+</sup> T cell counts were measured on weeks –2, 0, 1, 3, 5, 6, 9, 13, 17, 21 and 25. After resumption of ART, we monitored CD4<sup>+</sup> T cell count every fourth week until plasma HIV-1 RNA levels were undetectable (<50 copies per milliliter).

### 25-week analytical treatment interruption

At week 0, participants were instructed to discontinue ART the following day and continue off ART for 25 weeks unless one of four criteria was met. Details can be found in the study protocol.

### Plasma HIV-1 RNA measurements

Plasma HIV-1 RNA levels were measured with standardized clinical assays at every visit. After resumption of ART, we monitored plasma HIV-1 RNA every fourth week until levels were undetectable (<50 copies per milliliter).

### Doubling time of plasma HIV-1 RNA

The initial increase in plasma HIV-1 RNA was calculated based on the first two consecutive plasma HIV-1 RNA measurements that increased, and the second measurement had to increase by 1,000 copies per milliliter compared to the previous measurement. The slope of this increase was calculated using a linear regression model.

### bNAb sensitivity

bNAb sensitivity prediction was performed at screening for all participants primarily using the LabCorp–Monogram Biosciences PhenoSense HIV Monoclonal Antibody Assay on proviral HIV-1 DNA. bNAb sensitivity was a pre-specified inclusion criterion. For the PhenoSense assay, sensitivity was determined based on the concentration of bNAb required to inhibit viral replication by 90% ( $IC_{90}$ ). The sensitivity cutoffs were pre-defined as  $IC_{90} < 1.5$  for 3BNC117 and  $< 2.0 \mu\text{g ml}^{-1}$  for 10-1074 combined with a maximum percent inhibition (MPI) observed at the highest bNAb concentration tested  $\geq 98\%$ . If the PhenoSense assay did not yield a result (for example, due to insufficient amplification), *env* sequences obtained by single-genome amplification (SGA) of proviral HIV-1 DNA were secondarily analyzed using a genotypic prediction algorithm. For this genotypic assay, the pre-defined cutoff was  $> 90\%$  of sequences being sensitive to the bNAb for the proviral reservoir to be classified as 'sensitive'. If the *env* sequencing failed, the participant could still be enrolled based on the assumption of a lower HIV-1 reservoir size among these individuals (see the study protocol).

### Proviral HIV-1 *env* sequencing

For screening of participants who failed the PhenoSense assay and post hoc for all participants receiving the bNAb combination, SGA, sequencing and genotypic analysis were performed on proviral HIV-1 *env*. DNA was isolated from PBMCs using the DNeasy Blood and Tissue Kit (Qiagen), and Platinum Taq DNA Polymerase (Invitrogen) was used for SGA ( $< 30\%$  of wells containing *env*). The *env* amplification was conducted in 10- $\mu\text{l}$  reactions as nested PCRs. *env* amplification was, in most cases, first attempted with primers listed in the first box (Supplementary Table 4).

For participants in whom these primers did not amplify *env*, alternative primer sets and combinations were tested (second box, Supplementary Table 4). For a few of the participants, near full-length (NFL) HIV-1 sequencing was conducted to obtain sequences that could be used for individual *env* primer design. NFL amplification was conducted as SGA using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) in 10- $\mu\text{l}$  reactions. If the NFL sequences were resistant to one or both bNAbs, further analysis and amplification was not conducted.

All primer sequences, an overview of which primer set was used for each of the included participants and thermal cycler conditions can be found in Supplementary Table 4.

The *env*-positive wells were collected and prepared for sequencing<sup>6</sup>. In brief, tagmentation was conducted using TDE1 Tagment DNA Enzyme (Illumina) after ligation of barcoded primers using KAPA HiFi HotStart ReadyMix (Roche). The amplicons were pooled to one library, purified and paired-end sequenced on a MiniSeq (Illumina), using MiniSeq Mid-Output Kit (Illumina).

### Rebound plasma HIV-1 *env* sequencing

Plasma rebound virus was sequenced for participants who received bNAbs and rebounded within the study period or were viremic at the end of the 25-week ATI. Extraction of RNA, cDNA synthesis and SGA of plasma HIV<sup>6</sup>, library preparation and sequencing were conducted as for proviral HIV-1 *env* sequencing.

### HIV-1 sequence assembly and annotation

Assembly and annotation of HIV-1 sequences was performed by The Rockefeller University pipeline (Defective and Intact HIV Genome

Assembler)<sup>6</sup>. The pipeline implements quality control checks to remove PCR-amplified reads, correct errors, trim adaptors and low-quality bases and remove potential contaminant reads. Paired overlapping reads are merged and subsequently used to reconstruct HIV-1 contigs. The longest reconstructed HIV-1 contig is annotated by aligning it to HXB2 reference. Finally, sequences not classified as double peaks (cutoff consensus identity for any residue  $< 70\%$ ) are classified as intact or defective. Samples with  $< 500$  sequencing reads and sequences with double peaks were omitted from downstream analysis. Only intact HIV-1 *env*s were considered in the subsequent analysis.

**Sequence-based assessment of bNAb sensitivity.** The HIV-1 *env* sequences were analyzed for sensitivity to 3BNC117 and 10-1074 by searching for resistance mutations using a model based on sequencing and neutralization data (Supplementary Table 1).

### Plasma antiretroviral drug concentrations

Antiretroviral drug concentrations in plasma were determined at BioXpedia using liquid chromatography with tandem mass spectrometry (LC–MS/MS) assay for individuals not fulfilling the criteria for viral rebound at week 13. Two timepoints were analyzed: (1) week 0 and (2) end of study, defined as the timepoint for reaching criteria for viral rebound or week 25, whichever came first.

### Serum bNAb concentrations

Each bNAb concentration in human serum was quantitatively measured using a sandwich immunoassay on Meso Scale Discovery Electrochemiluminescence (MSD–ECL) platform at PPD Bioanalytical Lab. In this assay, the bNAb was captured by biotinylated anti-idiotypic anti-bNAb antibody coated onto an MSD streptavidin plate, which was then detected by SULFO-TAG-conjugated anti-idiotypic anti-bNAb antibody. The plate was read on an MSD plate reader, resulting in assay signal proportional to the concentration of each bNAb. The method was validated following current regulatory guidance, and a sensitivity of  $100 \text{ ng m}^{-1}$  was established for each pharmacokinetic assay. We measured the serum bNAb concentrations at weeks 0, 6, 13 and 25 after ATI.

We used multiple imputation to impute missing values in serum bNAb concentrations. A detailed description can be found in Supplementary Table 2.

### Intact HIV-1 proviruses

The IPDA is used to measure intact and defective HIV-1 proviruses by targeting the  $\Psi$  and RRE, which are frequently deleted or mutated in defective proviruses<sup>62</sup>. We applied the IPDA protocol for all individuals regardless of subtype and found 20% (8/40) of the participants with  $\Psi$ , RRE or  $\Psi$  and RRE failure. For RRE failure, an alternative primer/probe set, reported to correlate with the original IPDA RRE primer/probe set, designed by Kinloch et al.<sup>63</sup>, was tested; this primer/probe set is located slightly downstream of the original IPDA RRE primer/probe set<sup>63</sup>. This alternative primer/probe set rescued all participants with RRE failure ( $n = 5$ ) and worked for the participant with dual failure, thus leaving three participants with  $\Psi$  failure. For these three participants, the IPDA-like 3dPCR assay was applied, where individual primers and probes are designed for the participants based on sequencing of the participants' virus<sup>6</sup>. The level of intact proviruses measured by IPDA and 3dPCR were previously shown to strongly correlate in individuals with HIV-1 subtype B; thus, 3dPCR provides a reasonable estimate of intact HIV-1 reservoir size, although it is possible that the assay's positive predictive value for intact proviruses may, like the IPDA, vary between individuals<sup>64</sup>.

Regardless of the downstream assay applied—IPDA, IPDA with alternative RRE primer/probe or IPDA-like 3dPCR— $CD4^+$  T cells ( $CD4^+$  T Cell Isolation Kit, Miltenyi Biotec) were isolated from  $30 \times 10^6$  PBMCs, and genomic DNA was extracted (DNeasy Blood and Tissue Kit, Qiagen). IPDA, IPDA with alternative RRE primer/probe and the IPDA-like 3dPCR

were conducted<sup>6,62,63</sup>. An overview of the assay and primer/probe set used for each participant is provided in Supplementary Tables 3 and 4. In parallel with HIV-1 $\Psi$  and RRE, all DNA extracts were also assayed in a separate duplexed ddPCR reaction targeting the human *RPP30* gene<sup>63</sup>; primers and probes are listed in Supplementary Table 5; and a detailed description of the method can be found in Supplementary Table 6.

### HIV-1-specific T cell immunity

HIV-1-specific T cell immunity was assessed using the AIM assay by flow cytometry at weeks 0, 6, 13 and 25 after ATI. Aliquots of cryopreserved PBMCs were thawed, washed and rested at 37 °C for 3 h. Cells were then plated into wells of a 96-well plate at a total of  $1 \times 10^6$  PBMCs per well in RPMI glutamine supplemented with penicillin–streptomycin and 10% FBS. Cells were then stimulated at a final concentration of 2  $\mu\text{g ml}^{-1}$  of total peptide with four different HIV peptide pools for 20 h at 37 °C. Detailed description of the methods can be found in Supplementary Table 7, and the gating strategy can be found in Supplementary Fig. 1.

### Cytokine detection

Cytokine detection of IFN- $\gamma$  and GzmB were measured in supernatants from Gag and non-stimulated AIM assay using MSD U-PLEX Custom Immuno-Oncology (K151AEM-2) according to the manufacturer's instructions. The concentration of IFN- $\gamma$  ( $\text{pg ml}^{-1}$ ) and GzmB ( $\text{pg ml}^{-1}$ ) in the supernatant of Gag-specific cells (AIM<sup>+</sup> cells) was determined by subtracting the concentration of the non-stimulation condition from the stimulated condition.

### HLA class I typing

HLA class I (HLA-A, HLA-B and HLA-C) alleles were genotyped at the American Safety and Health Institute-accredited laboratory HistoGenetics using sequence-based typing.

### Outcomes

The primary endpoint was time to loss of virological control during ATI (sustained plasma HIV-1 RNA  $\geq 1,000$  copies per milliliter for 4 weeks or confirmed plasma HIV-1 RNA  $>100,000$  copies per milliliter). Secondary endpoints were (1) safety, including CD4<sup>+</sup> T cell counts, and (2) viral kinetics during ATI: time to plasma HIV-1 RNA  $>50$  and  $>1,000$  copies per milliliter as well as doubling time of the initial increase in plasma HIV-1 RNA. Exploratory endpoints were (1) changes in reservoir size measured by intact HIV-1 proviruses and (2) effects on HIV-1-specific T cell immunity using the AIM assay.

### Statistical methods

The analyses performed on primary, secondary and exploratory endpoints were pre-specified in the protocol. Paired two-tailed Wilcoxon tests and two-tailed Mann–Whitney tests were used to analyze non-parametric outcomes within and between groups, respectively. When more than two groups were compared, the Kruskal–Wallis test was used. Data are presented as median (IQR), median (range) or mean  $\pm$  s.d. as indicated in each respective figure legend. The Kaplan–Meier estimator was used to assess the magnitude of the difference between the survival curves, and the log-rank test was used to compare time to loss of virologic control during ATI between groups. For correlations, Spearman's correlation coefficient was used. We used the full analysis set, comprising all individuals receiving at least one dose of active treatment with assessable data, for the efficacy analyses and all enrolled individuals for the safety analyses. We used Stata version 17.0 and Prism version 7.0 software for statistical analyses.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Data are not available for download due to privacy/ethical restrictions under the European Union General Data Protection Regulation. Specific requests for access to the trial data may be sent to olesoega@rm.dk, and access may be provided to a named individual in agreement with the rules and regulations (<https://www.datatilsynet.dk/english/legislation>) of the Danish Data Protection agency and the Danish National Center for Ethics with a 2-week response timeframe for requests.

All viral sequences have been deposited in GenBank with accession numbers OR014503 to OR015782 ([www.ncbi.nlm.nih.gov/nucleotide/](http://www.ncbi.nlm.nih.gov/nucleotide/)).

### References

- Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Trials* **11**, 32 (2010).
- Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inform.* **42**, 377–381 (2009).
- Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. *J. Biomed. Inform.* **95**, 103208 (2019).
- Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. *Nat. Med.* **24**, 1701–1707 (2018).
- Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature* **522**, 487–491 (2015).
- Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature* **566**, 120–125 (2019).
- Kinloch, N. N. et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). *Nat. Commun.* **12**, 165 (2021).
- Gaebler, C. et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. *J. Exp. Med.* (2019). <https://doi.org/10.1084/jem.20190896>

### Acknowledgements

We thank all study participants who devoted time to our research as well as every clinical research unit involved in the study. We acknowledge The Rockefeller University for providing 3BNC117 and 10-1074 and Mologen AG (now part of Gilead Sciences, Inc.) for providing lefitolimod. The funders were not involved in the study design/operations, data collection/analysis/interpretation or preparation of the manuscript. The study was funded through a Gilead HIV Cure grant to O.S.S. Study drugs were donated free of charge by The Rockefeller University (3BNC117 and 10-1074) and Mologen AG/Gilead Sciences, Inc. (lefitolimod) for use in this trial. J.D.G. is supported by the Lundbeck Foundation (R381–2021–1405). P.W.D. is supported by the National Institute of General Medical Sciences of the National Institutes of Health under award P20 GM103427. Partial support for virologic analysis was provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award R01AI47845 (RBJ), supported by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, the National Institute on Drug Abuse and the National Heart, Lung, and Blood Institute. S.R.L. is supported by funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award UM1AI126611-01 and the National Health and Medical Research Council (NHMRC) of Australia (1135851 and 1149990). S.R.L. is an

NHMRC Practitioner Fellow. O.S.S. is also supported by the Danish Council for Independent Research (grant 9060-00023B) and the Lundbeck Foundation (R313-2019-790). None of the specific sources of funding had any role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript.

### Author contributions

O.S.S. developed the trial design. J.F.H., M.H.P., P.W.D., M.T., M.C.N., M.C. and O.S.S. wrote the protocol. J.D.G., J.F.H., B.S., J.M., H.N., I.S.J., T.B., S.L., J.G., L.Ø., L.V., N.W., A.M.D.R., K.B.H.P., J.L., S.R.L., T.A.R., D.H.R. and O.S.S. did the clinical visits. J.D.G., M.H.P., M.R.U., M.H.S., R.O., D.C.C.J., N.L., T.T.H., V.R., R.B.J., M.T. and O.S.S. did the laboratory assays and validations. V.R. performed the bioinformatic analysis. J.D.G., M.H.P., M.R.U. and H.S. did the statistical analysis. J.D.G., M.H.P., M.R.U. and O.S.S. drafted the tables and figures. J.D.G. and O.S.S. drafted the article, which all authors critically revised for important intellectual content. J.D.G. and O.S.S. had full access to all the data in the study, verified the data and had final responsibility for the decision to submit for publication.

### Competing interests

M.C.N. is listed as an inventor on patents for the antibodies 3BNC117 and 10-1074. All other authors declare no competing interests.

### Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-023-02547-6>.


**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02547-6>.

**Correspondence and requests for materials** should be addressed to Ole S. Sogaard.


**Peer review information** *Nature Medicine* thanks Kathryn Stephenson, Alejandro Balazs and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Alison Farrell, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).





**Extended Data Fig. 1 | A comprehensive CONSORT Flow Diagram.** ART, antiretroviral therapy; ATI, ART interruption; bNAb, broadly neutralizing antibody, SAE, severe adverse event.




Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | Time to plasma HIV-1 RNA above 50 and 1,000 copies/mL during 25 weeks of ATI.** (a–h) Kaplan–Meier curves showing the percentage of individuals still interrupting ART with plasma HIV-1 RNA < 50 and <1,000 copies/mL during the 25 weeks of ATI for the three active interventional groups compared to the placebo/placebo group: Lefitolimod/placebo (a, e), placebo/bNAb (b, f) and lefitolimod/bNAb (c, g). Kaplan–Meier curves showing the

percentage of individuals still interrupting ART with plasma HIV-1 RNA < 50 and <1,000 copies/mL during the 25 weeks of ATI for the placebo/bNAb group compared to the lefitolimod/bNAb group (d, h). *P* values were calculated using the log-rank test. ART, antiretroviral therapy; ATI, ART interruption; bNAb, broadly neutralizing antibody.


Partial ART-free virologic control, whom re-started ART as indicated



**g**

Clinical Characteristics	ID202	ID106	ID601	ID114
Age (years)	57	52	52	31
Sex	Male	Female	Male	Male
Race and ethnicity	White	White	White	White
Time since HIV-1 diagnosis (years)	9	23	14	7
Time from HIV-1 diagnosis to ART (years)	5	0	3	1
Time on ART (years)	4	23	11	6
HIV-1 subtype	B	B	B	B
Baseline CD4+ T cell count (cells/mm <sup>3</sup> )	694	830	1,114	700
pre-ATI: Intact HIV-1 proviruses (copies/10 <sup>6</sup> CD4+ T cells)	NA	663.7	5.7	140.3
25-week ATI: Intact HIV-1 proviruses (copies/10 <sup>6</sup> CD4+ T cells)	NA	2,315.1	313.9	170.7
pre-ATI: HIV-1-specific CD8+ T cell response (%)	3.7	2.4	1.3	2.3
25-week ATI: HIV-1-specific CD8+ T cell response (%)	13.7	8.6	1.2	2.9
HLA-A1	24:02:01G	02:01:01G	23:01:01G	02:01:01G
HLA-A2	32:01:01G	29:02:01G	24:02:01G	03:01:01G
HLA-B1	40:02:01G	15:01:01G	27:05:02G	40:01:01G
HLA-B2	51:01:01G	44:03:01G	39:01:01G	40:01:01G
HLA-C1	01:02:01G	03:04:01G	02:02:02G	03:04:01G
HLA-C2	02:02:02G	16:01:01G	12:03:01G	03:04:01G

Ongoing complete ART-free virologic control



**h**

Clinical Characteristics	ID142	ID314
Age (years)	57	55
Sex	Male	Female
Race and ethnicity	White	White
Time since HIV-1 diagnosis (years)	5	2
Time from HIV-1 diagnosis to ART (years)	0	0
Time on ART (years)	5	2
HIV-1 subtype	B	NA
Baseline CD4+ T cell count (cells/mm <sup>3</sup> )	1,250	1,030
pre-ATI: Intact HIV-1 proviruses (copies/10 <sup>6</sup> CD4+ T cells)	220.2	<1.2
25-week ATI: Intact HIV-1 proviruses (copies/10 <sup>6</sup> CD4+ T cells)	134.8	<1.2
pre-ATI: HIV-1-specific CD8+ T cell response (%)	2.7	4.9
25-week ATI: HIV-1-specific CD8+ T cell response (%)	3.5	2.7
HLA-A1	01:01:01G	30:01:01G
HLA-A2	02:01:01G	32:01:01G
HLA-B1	08:01:01G	13:02:01G
HLA-B2	44:02:01G	51:01:01G
HLA-C1	05:01:01G	06:02:01G
HLA-C2	07:01:01G	14:02:01G


Extended Data Fig. 3 | See next page for caption.



**Extended Data Fig. 3 | Plasma HIV-1 RNA kinetics for participants with partial and ongoing complete ART-free virologic control during the 25 weeks of ATI.** (a-d) Individual plasma HIV-1 RNA levels are shown in the four participants (ID202, ID106, ID601 and ID114) with partial ART-free virologic control during 25 weeks of ATI, whom re-started ART as indicated. (e, f) Individual plasma HIV-1 RNA levels are shown in the two participants (ID142 and ID314) with ongoing complete ART-free virologic control during 25 weeks of ATI. Solid green arrows indicate lefitolimod injections. Solid red and blue triangles indicate 3BNC117 and 10-1074 infusions, respectively. Empty green arrows as well as red and blue triangles indicate placebo injections or infusions, respectively. Plasma HIV-1 RNA


(group-colored symbols with line; left y-axis) and bNAbs serum concentrations (3BNC117, solid red square with line; 10-1074, solid blue triangle with line; right y-axis) during ATI, ID601 did not have serum samples taken. Light grey shaded areas indicate time on ART, while white shaded areas indicate still interrupting ART. The vertical dotted line at week 25 indicates end-of-study time point.

(g-h) Overview of the clinical characteristics for participants with partial and ongoing complete ART-free virologic control during the 25 weeks of ATI. ART, antiretroviral therapy; ATI, ART interruption; bNAbs, broadly neutralizing antibody; HLA, human leukocyte antigen; NA, not available; i.v., intravenous; s.c., subcutaneous.




**Extended Data Fig. 4 | bNAb sensitivity at screening for the placebo/placebo and lefitolimod/placebo groups.** bNAb sensitivity was primarily analyzed using the PhenoSense Monoclonal Antibody Assay with predefined IC90 thresholds for 3BNC117 (<1.5 µg/mL) and 10-1074 (<2.0 µg/mL) and maximum percentage inhibition (MPI) ≥98%. In seven participants, the PhenoSense Assay failed, and we secondarily used proviral HIV-1 envelope (*env*) sequences on a genotypic prediction algorithm with predefined thresholds of ≥90% known sequences are sensitive. Two participants (ID141 and ID313) were enrolled based upon the genotypically analysis, but post-hoc phenotypic data showed IC90 values of 3.69 and 3.59 µg/mL for 3BNC117, respectively. In another two participants (ID614

and ID808), both the PhenoSense Assay and *env* sequencing initially failed, and we tertiary-included (see Methods) these individuals based on the assumption that both assays failed due to a very small reservoir size. Empty red and blue triangles indicate placebo for 3BNC117 and 10-1074 infusions, respectively. Light grey shaded areas indicate time on ART, while white shaded boxes indicate still interrupting ART during the 25 weeks of ATI. Dark grey boxes are assay failures and pink boxes are no attempt to amplify. ART, antiretroviral therapy; ATI, ART interruption; *env*; HIV-1 envelope; IC90, concentration of bNAb required for 90% inhibition; i.v., intravenous.




**Extended Data Fig. 5 | Fraction and size of the defective HIV-1 proviruses.** Mean fraction of intact, 3' and 5' defective HIV-1 proviruses per 10<sup>6</sup> CD4+ T cells from 39 individuals at ATI start (day 0) (a). The size of the 3' (b) and 5' (c) defective HIV-1 reservoir at ATI start (day 0) and after 6, 13 and 25 weeks of ATI among individuals in the four randomization groups (lines at median and IQRs). Placebo/placebo group (n = 10); lefotimod/placebo (n = 9); placebo/bNAb (n = 10); and lefotimod/bNAb (n = 11). All weeks are shown, including weeks with no data available. Median change in the 3' (d) and 5' (e) defective HIV-1 reservoir between

week 6 of the ATI and pre-ATI for the four randomization groups are shown. Data are median and IQRs with the placebo/placebo group as the reference. Placebo/placebo group (n = 10); lefotimod/placebo (n = 8); placebo/bNAb (n = 9); and lefotimod/bNAb (n = 9). P values comparing within groups (only P values below 0.05 are shown) and between groups were calculated using the paired two-tailed Wilcoxon test and two-tailed Mann-Whitney test, respectively. ART, antiretroviral therapy; ATI, ART interruption; IQR, interquartile ranges; bNAb, broadly neutralizing antibody.



**Extended Data Fig. 6 | HIV-1-specific CD8+ and CD4+ immune responses during ATI.** (a) Correlation between fold change of HIV-1-specific CD8 + T cell response from pre-ATI to week 6 of ATI and measurable plasma HIV-1 RNA at week 6 with for participants with plasma HIV-1 RNA > 50 copies/mL. Placebo/placebo group (n = 9); lefitolimod/placebo (n = 7); placebo/bNAb (n = 2); and lefitolimod/bNAb (n = 1). *P* value calculated using two-tailed Spearman's correlation coefficient. (b-d) Dot plot of median fold change in Gag-specific CD8 + T cells and Gag-induced IFN- $\gamma$  or GzmB responses after 13 weeks of ATI among individuals with either plasma HIV-1 RNA below (left panel) or above (right panel) 50 copies per mL in the two randomization groups receiving bNAb combination (lines at median and IQRs). Plasma HIV-1 RNA below 50 copies/mL: Placebo/bNAb (n = 5);

and lefitolimod/bNAb (n = 1), or above 50 copies/mL: Placebo/bNAb (n = 5); and lefitolimod/bNAb (n = 7 to 9). *P* values comparing within groups were calculated using the paired two-tailed Wilcoxon test. (e) Dot plot of the frequency of HIV-1-specific CD4 + T cells at ATI start (day 0) and after 6, 13 and 25 weeks of ATI among individuals in the four randomization groups (lines at median and IQRs). All weeks are shown, including weeks with no data available. Placebo/placebo group (n = 10); lefitolimod/placebo (n = 9); placebo/bNAb (n = 11); and lefitolimod/bNAb (n = 12). *P* values comparing within groups were calculated using the paired two-tailed Wilcoxon test. Only *P* values below 0.05 are shown. ART, antiretroviral therapy; ATI, ART interruption; bNAb, broadly neutralizing antibody; IQR, interquartile ranges.



**b**

Δ Trial start to time of re-suppression (plasma HIV-1 RNA < 50 copies/mL) after re-starting ART	Median change in CD4+ T cell count per mm <sup>3</sup>		
	Median	IQR	P
Placebo/placebo	-38	-146 to 46	Ref
Leflotimod/placebo	-120	-249 to 30	0.58
Placebo/bNAb	-105	-140 to 184	0.61
Leflotimod/bNAb	-130	-210 to -23	0.45

**Extended Data Fig. 7 | CD4 + T cell count at trial start and end-of-study.** (a) Dot plots of the CD4 + T cell count in the four groups at trial start (week -2) and end-of-study (lines at median and IQRs). Placebo/placebo group (n = 10); lefotimod/placebo (n = 10); placebo/bNAb (n = 11); and lefotimod/bNAb (n = 12). P values comparing within groups were calculated using the paired two-tailed Wilcoxon test. (b) Median change in CD4 + T cell count in the four groups

between time point of viral suppression (plasma HIV-1 RNA < 50 copies/mL) and trial start are shown. Data are median and IQRs with the placebo/placebo group as the reference. Placebo/placebo group (n = 8); lefotimod/placebo (n = 7); placebo/bNAb (n = 6); and lefotimod/bNAb (n = 10). P values between groups were calculated using the two-tailed Mann-Whitney test. bNAb, broadly neutralizing antibody; IQR, interquartile ranges.



Extended Data Table 1 | Individual characteristics of the study population at baseline

HIV-1 subtype	HLA class I alleles						Time since HIV-1 diagnosis (years)	Time from HIV-1 diagnosis to ART (years)	Time on ART (months)	Presumed time from infection to ART (months)	CD4+ T cells (per mm <sup>3</sup> )	ART regimen	Intact HIV-1 proviruses (copies/10 <sup>8</sup> CD4+ T cells)		
	A1	A2	B1	B2	C1	C2									
Placebo/placebo (n=11)	104	B	01:01:01G	11:01:01G	07:02:01G	35:01:01G	04:01:01G	07:02:01G	12	0	12	14	730	ABA, 3TC, DTG	1.2
	105	B	02:01:01G	03:01:01G	14:02:01G	44:02:01G	05:01:01G	08:02:01G	9	2	7	29	850	ABA, 3TC, DRV/c	NA
	112	NA	25:01:01G	30:02:01G	18:01:01G	18:01:01G	05:01:01G	12:03:01G	18	0	18	120	700	ABA, 3TC, DTG	54.2
	141	B	02:01:01G	03:01:01G	07:02:01G	18:01:01G	07:02:01G	12:03:01G	11	0	11	NA	750	3TC, DTG	37.1
	205	B	02:01:01G	11:01:01G	07:02:01G	44:03:01G	04:01:01G	07:02:01G	7	0	7	NA	1,434	TAF, FTC, DRV	37.0
	502	B	02:01:01G	68:01:02G	14:01:01G	15:01:01G	03:03:01G	08:02:01G	37	14	23	NA	740	ABA, 3TC, DRV/r	42.2
	607	NA	02:01:01G	68:02:01G	14:02:01G	15:01:01G	03:03:01G	08:02:01G	9	0	9	82	787	TAF, FTC, BIC	49.4
	814	B	02:01:01G	33:03:01G	07:02:01G	58:01:01G	03:02:01G	07:02:01G	4	0	4	0	708	TAF, FTC, DTG	1.2
	808	NA	03:01:01G	11:01:01G	35:01:01G	56:01:01G	01:02:01G	04:01:01G	5	0	5	10	743	TDF, FTC, DRV/c	1.2
	816	B	01:01:01G	11:01:01G	08:01:01G	44:02:01G	05:01:01G	07:01:01G	13	5	8	76	507	TAF, FTC, BIC	204.9
	817	B	23:01:01G	24:02:01G	08:04:01	44:03:01G	04:01:01G	07:01:01G	13	8	5	104	820	3TC, DTG	1,031.1
Leflunomide/placebo (n=11)	115	NA	02:01:01G	03:01:01G	07:02:01G	18:01:01G	07:02:01G	07:01:01G	15	1	14	29	1,100	TAF, FTC, DTG	24.5
	134	B	02:01:01G	24:02:01G	07:02:01G	35:01:01G	04:01:01G	07:02:01G	15	1	14	NA	540	TAF, FTC, BIC	41.9
	202	B	24:02:01G	32:01:01G	40:02:01G	51:01:01G	01:02:01G	02:02:02G	9	5	4	67	694	TDF, FTC, DTG	NA
	304	NA	02:01:01G	26:01:01G	35:43:01	41:02:01G	01:02:01G	17:01:01G	13	2	11	NA	620	TDF, FTC, DTG	82.6
	313	C	29:02:01G	33:01:01G	08:01:01G	58:01:01G	07:01:01G	07:01:01G	8	0	8	NA	750	3TC, DTG	1.2
	411	CRF02	11:01:01G	11:01:01G	18:01:01G	51:01:01G	07:01:01G	15:13:01	1	0	1	0	614	TDF, FTC, DTG	2,576.6
	501	B	02:01:01G	24:02:01G	40:01:01G	57:01:01G	03:04:01G	06:02:01G	12	2	10	NA	920	TDF, FTC, DTG	40.0
	603	B	24:02:01G	32:01:01G	13:02:01G	35:02:01G	04:01:01G	06:02:01G	8	0	8	11	837	RLP, DTG	186.3
	802	B	03:01:01G	29:02:01G	08:01:01G	56:01:01G	01:02:01G	07:01:01G	12	2	10	33	621	ABA, 3TC, DTG	60.9
	810	C	NA	NA	NA	NA	NA	NA	5	0	5	25	1,025	TAF, FTC, BIC	NA
	814	G	11:01:01G	24:02:01G	07:05:01G	49:01:01G	07:01:01G	15:05:01G	13	4	9	59	635	TDF, FTC, RAL	1.2
Placebo/bNAb (n=12)	106	B	02:01:01G	29:02:01G	15:01:01G	44:03:01G	03:04:01G	16:01:01G	23	0	23	79	830	ABA, 3TC, NVP	663.7
	109	B	02:01:01G	02:01:01G	07:02:01G	51:01:01G	04:01:01G	07:02:01G	5	0	5	170	1,250	ABA, 3TC, DTG	93.5
	119	B	01:01:01G	01:01:01G	08:01:01G	57:01:01G	06:02:01G	07:01:01G	13	3	10	NA	800	TAF, FTC, BIC	77.4
	133	B	02:01:01G	32:01:01G	15:01:01G	40:02:01G	02:02:02G	03:04:01G	29	21	8	1,292	910	ABA, 3TC, DTG	33.0
	142	B	01:01:01G	02:01:01G	08:01:01G	44:02:01G	05:01:01G	07:01:01G	5	0	5	4	1,210	TAF, FTC, BIC	220.2
	204	B	03:01:01G	11:01:01G	07:02:01G	35:01:01G	04:01:01G	07:02:01G	9	2	7	24	1,024	TAF, FTC, BIC	NA
	314	NA	30:01:01G	32:01:01G	13:02:01G	51:01:01G	06:02:01G	14:02:01G	2	0	2	NA	1,030	TDF, FTC, DTG	1.2
	601	B	23:01:01G	24:02:01G	27:05:02G	39:01:01G	02:02:02G	12:03:01G	14	3	11	40	1,114	TDF, FTC, DTG	5.7
	805	C	02:01:01G	24:02:01G	40:01:01G	40:01:01G	03:04:01G	03:04:01G	6	0	6	5	699	TDF, FTC, DTG	43.3
	807	C	02:01:01G	02:05:01G	07:02:01G	07:05:01G	07:02:01G	07:02:01G	12	0	12	NA	1,561	NA, DTG	442.7
	809	B	01:01:01G	03:01:01G	08:01:01G	08:01:01G	07:01:01G	07:01:01G	17	4	13	54	520	3TC, DTG	8.4
	818	B	02:01:01G	24:02:01G	15:01:01G	51:01:01G	03:04:01G	15:02:01G	4	0	4	1,330	1,582	3TC, DRV/c	NA
Leflunomide/bNAb (n=12)	101	CRF01	11:01:01G	23:01:01G	35:01:01G	49:01:01G	04:01:01G	07:01:01G	17	0	17	NA	610	ABA, 3TC, TDF	134.4
	114	B	02:01:01G	03:01:01G	40:01:01G	40:01:01G	03:04:01G	03:04:01G	7	1	6	22	700	TDF, FTC, DRV/c	140.3
	117	B	11:01:01G	24:02:01G	15:24:01	39:01:01G	03:03:01G	07:02:01G	26	0	26	28	540	TDF, FTC, DTG	73.6
	139	B	02:01:01G	03:01:01G	07:02:01G	07:02:01G	03:04:01G	07:02:01G	4	0	4	NA	1,590	TAF, FTC, BIC	346.0
	143	B	01:01:01G	68:02:01G	14:02:01G	39:01:01G	07:01:01G	08:02:01G	7	0	7	8	1,030	TDF, FTC, DTG	NA
	312	B	01:01:01G	24:02:01G	08:01:01G	39:06:02G	07:02:01G	07:01:01G	3	0	3	NA	790	TDF, FTC, RAL	313.3
	412	B	11:01:01G	24:02:01G	18:01:01G	35:03:01G	04:01:01G	07:01:01G	2	0	2	9	2,100	TDF, FTC, DRV/r	50.1
	609	B	02:01:01G	24:02:01G	15:01:01G	49:01:01G	03:04:01G	07:01:01G	16	7	9	NA	925	TAF, FTC, DTG	97.8
	801	B	02:01:01G	31:01:02G	15:01:01G	18:01:01G	03:03:01G	07:01:01G	9	1	8	NA	833	ABA, 3TC, DTG	94.2
	813	B	02:01:01G	02:01:01G	35:01:01G	40:01:01G	03:04:01G	04:15:02	3	0	3	6	1,778	TDF, FTC, DRV/c	1.2
	815	B	01:01:01G	02:01:01G	08:01:01G	15:01:01G	04:01:01G	07:01:01G	11	0	11	NA	831	ABA, 3TC, DTG	66.2
	822	B	02:01:01G	24:02:01G	07:02:01G	44:02:01G	05:01:01G	07:02:01G	15	2	13	1,232	797	3TC, DTG	94.2

ABA, abacavir; ART, antiretroviral therapy; BIC, bictegravir; bNAb, broadly neutralizing antibody; CRF, circulating recombinant form; c, cobiscistat; DRV, darunavir; DTG, dolutegravir; FTC, emtricitabine; HLA, human leukocyte antigen; NA, not available; NVP, nevirapine; RAL, raltegravir; r, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.

Extended Data Table 2 | AEs by group

	Placebo+placebo (n=11)				Leflitomolod+placebo (n=11)				Placebo+bNAb (n=12)				Leflitomolod+bNAb (n=12)			
	Participants	Mild	Mod.	Sev.	Participants	Mild	Mod.	Sev.	Participants	Mild	Mod.	Sev.	Participants	Mild	Mod.	Sev.
<b>Events related to lefitomolod</b>	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Any	7	64	-	-	5	45	-	-	5	42	-	-	9	75	-	-
Injection site reaction	5	45	5	-	3	27	12	-	2	17	4	-	8	67	27	-
Fatigue	4	36	4	-	3	27	3	1	-	-	-	-	2	17	2	-
Headache	-	-	-	-	1	9	3	-	1	8	1	-	2	17	4	-
Herpes simplex reactivation	1	9	1	-	1	9	1	-	2	17	1	1	1	8	1	-
Hyperhidrosis	-	-	-	-	1	9	1	-	1	8	1	-	2	17	2	-
Flu like symptoms	1	9	1	-	1	9	1	-	-	-	-	-	1	8	1	1
Malaise	1	9	1	-	1	9	2	-	-	-	-	-	1	8	-	1
Hot flashes	-	-	-	-	-	-	-	-	1	8	1	-	2	17	1	1
Diarrhea	1	9	1	-	-	-	-	-	-	-	-	-	1	8	2	-
Fever	-	-	-	-	2	18	4	-	-	-	-	-	-	-	-	-
Nausea	-	-	-	-	1	9	1	-	-	-	-	-	1	8	2	-
Back pain	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Dysgeusia	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Insomnia	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Myalgia	1	9	3	-	-	-	-	-	-	-	-	-	-	-	-	-
Neutrophil count decreased	1	9	-	1	-	-	-	-	-	-	-	-	-	-	-	-
Pain in extremity	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Platelet count decreased	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Pruritus	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Rash acneiform	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Rhinorrhea	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Shingles	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
SKin papilloma	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Stomach pain	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Tremor	1	9	-	1	-	-	-	-	-	-	-	-	-	-	-	-
White blood cell decreased	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
<b>Subtotal</b>	-	-	<b>19</b>	<b>2</b>	-	-	<b>30</b>	<b>3</b>	-	-	<b>10</b>	<b>1</b>	-	-	<b>45</b>	<b>3</b>
<b>Events related to bNAbs</b>	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Any	1	9	-	-	2	18	-	-	6	50	-	-	4	33	-	-
Fatigue	-	-	-	-	-	-	-	-	3	25	2	1	2	17	2	-
Hot flashes	-	-	-	-	1	9	1	-	1	8	1	-	1	8	2	-
Headache	-	-	-	-	1	9	1	-	1	8	1	-	-	-	-	-
Dizziness	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Hyperhidrosis	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Hypotension	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Infusion related reaction	-	-	-	-	-	-	-	-	1	8	-	1	-	-	-	-
Injection site reaction	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Nausea	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cardiac chest pain	-	-	-	-	-	-	-	-	1	8	-	1	-	-	-	-
<b>Subtotal</b>	-	-	<b>2</b>	-	-	-	<b>2</b>	-	<b>4</b>	<b>2</b>	<b>1</b>	-	-	<b>7</b>	-	-
<b>Events related to lefitomolod + bNAbs</b>	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Any	4	36	-	-	3	27	-	-	2	17	-	-	6	50	-	-
Fatigue	2	18	3	-	1	9	1	-	-	-	-	-	3	25	3	1
Chills	1	9	1	-	-	-	-	-	-	-	-	-	2	17	2	-
Headache	1	9	1	-	1	9	1	-	1	8	1	-	-	-	-	-
Hot flashes	-	-	-	-	-	-	-	-	-	-	-	-	2	17	2	-
Abdominal pain	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Arthralgia	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Constipation	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Fever	-	-	-	-	1	9	2	-	-	-	-	-	-	-	-	-
Flu like symptoms	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Herpes simplex reactivation	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Insomnia	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Malaise	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Mucositis oral	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Rash acneiform	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Rhinorrhea	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Watery eyes	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
<b>Subtotal</b>	-	-	<b>5</b>	-	-	-	<b>6</b>	-	<b>4</b>	<b>1</b>	-	-	<b>12</b>	<b>1</b>	-	-
<b>Total related</b>	-	-	<b>26</b>	<b>2</b>	-	-	<b>38</b>	<b>3</b>	-	-	<b>18</b>	<b>4</b>	<b>1</b>	-	<b>64</b>	<b>4</b>
<b>Unrelated Events</b>	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Any	10	91	-	-	5	45	-	-	11	92	-	-	10	83	-	-
Eczema	2	18	2	-	1	9	1	-	1	8	1	-	2	17	2	-
COVID-19	3	27	3	1	-	-	-	-	2	17	2	-	1	8	1	-
Headache	1	9	1	-	1	9	1	-	1	8	1	-	2	17	1	1
Back pain	1	9	1	-	-	-	-	-	2	17	1	1	1	8	1	-
Malaise	-	-	-	-	1	9	1	-	2	17	2	-	1	8	-	1
Nausea	1	9	1	-	1	9	1	-	1	8	1	-	1	8	-	1
Diarrhea	1	9	1	-	-	-	-	-	1	8	1	-	1	8	1	-
Flu like symptoms	-	-	-	-	-	-	-	-	2	17	1	1	1	8	1	-
Injection site reaction	1	9	1	-	1	9	1	-	-	-	-	-	1	8	1	-
Vomiting	-	-	-	-	1	9	1	-	1	8	1	-	1	8	-	1
Arthritis	-	-	-	-	-	-	-	-	1	8	1	1	1	8	3	-
Bruising	-	-	-	-	-	-	-	-	1	8	1	-	1	8	1	-
Chills	-	-	-	-	-	-	-	-	1	8	1	-	1	8	1	-
Herpes simplex reactivation	1	9	1	-	-	-	-	-	1	8	1	-	-	-	-	-
Insomnia	1	9	1	-	-	-	-	-	1	8	1	-	-	-	-	-
Lung infection	1	9	-	1	1	9	1	-	-	-	-	-	-	-	-	-
Lymph node pain	2	18	2	-	-	-	-	-	-	-	-	-	-	-	-	-
Rhinitis infective	-	-	-	-	-	-	-	-	1	8	1	-	1	8	1	-
Rhinorrhea	-	-	-	-	-	-	-	-	2	17	2	-	-	-	-	-
Upper respiratory infection	1	9	1	-	-	-	-	-	-	-	-	-	1	8	1	-
Vasovagal reaction	-	-	-	-	-	-	-	-	-	-	-	-	2	17	1	1
Abdominal pain	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Alanine aminotransferase increased	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Allergic reaction	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Anal hemorrhage	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-
Enterocolitis	1	9	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Erectile dysfunction	-	-	-	-	-	-	-	-	1	8	-	1	-	-	-	-
Gastritis	-	-	-	-	1	9	1	-	-	-	-	-	-	-	-	-
Hematoma	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Hemoglobin increased	1	9	-	1	-	-	-	-	-	-	-	-	-	-	-	-
Hot flashes	-	-	-	-	-	-	-	-	-	-	-	-	1	8	2	-
Hyperhidrosis	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Hypertension	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-
Mucositis oral	-	-	-	-	-	-	-	-	1	8	1	-	-	-	-	-
Myalgia	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	-



## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** Study data were collected and managed in Research Electronic Data Capture (REDCap) electronic data capture tools version 13.1.29 hosted at the Clinical Trial Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

**Data analysis** We used Stata version 17.0, Prism version 7.0 for statistical analyses, and QuantaSoft software (BioRad, version 1.7.4).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data are not available for download due to privacy/ethical restrictions under the EU GDPR. Specific requests for access to the trial data may be sent to olesoega@rm.dk and access may be provided to a named individual in agreement with the rules and regulations (<https://www.datatilsynet.dk/english/legislation>) of the Danish Data Protection agency and the Danish National Center for Ethics with a 2-week response time-frame to requests.

All viral sequences have been deposited in GenBank with accession numbers OR014503 to OR015782 ([www.ncbi.nlm.nih.gov/nucleotide/](http://www.ncbi.nlm.nih.gov/nucleotide/)).

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	The results were not disaggregated by sex and gender due to the nature of the design and sample size.
Reporting on race, ethnicity, or other socially relevant groupings	The results were not disaggregated by race, ethnicity or other socially relevant groupings due to the nature of the design and sample size.
Population characteristics	People living with HIV-1 aged 18-65 years on ART for at least 18 months, with plasma HIV-1 RNA <50 copies/mL for at least 15 months, and a CD4 T cell count >500 cells/mm <sup>3</sup> at screening.
Recruitment	<p>This was a phase 2a, investigator-initiated, randomized placebo-controlled, double-blinded international multicenter trial enrolling at six sites in Denmark, one site in Norway and one site in Australia.</p> <p>Participants were recruited in the out-patient clinics or invited to a pre-screening meeting through invitations. Recruitment may have been bias towards socioeconomically advantaged individuals wanting to participate more than socioeconomically disadvantaged individuals, but recruitment was based among others on CD4+ T cell count as well as plasma HIV-1 RNA levels and not on socioeconomic data, which is an inherent bias in clinical trials, but here counteracted by study design.</p>
Ethics oversight	<p>The protocol was approved by the Danish Medicine Authorities (#2018092874) and the Norwegian Medicines Agency (#20/16305-25) as well as the National Committee on Health Research Ethics in Denmark (#1-10-72-292-18), the Regional Committee on Medical and Health Research Ethics in Norway (#184485) and the Alfred Human Research Ethics Committee in Australia (#Project 258/20).</p> <p>The study was monitored by the Danish Good Clinical Practice Units (<a href="https://gcp-enhed.dk/">https://gcp-enhed.dk/</a>) in Denmark and Australia and by the Section for Monitoring, Clinical Trial Unit, Oslo (<a href="https://www.ous-research.no/ctu/">https://www.ous-research.no/ctu/</a>) in Norway.</p>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>Of the total 46 participants enrolled in the study, 43 received the random allocation treatment.</p> <p>The sample size calculation was based on the primary endpoint: time to viral rebound during ATI. Time from stopping ART to loss of virological control was compared in the four randomization groups. If loss of virological control occurred, the date of the last measurement of plasma HIV-1 RNA <math>\geq 1,000</math> copies/mL or confirmed <math>&gt;100,000</math> copies/mL was defined as “date of viral rebound”. Using a 2-sample comparison of means with a standard deviation (s.d.) of 11 days, 10 evaluable participants in each of the two groups would have 90% power to detect <math>\geq 16</math> days difference in time to viral rebound at a 5% significance level. To accommodate for dropouts, we aimed for 12 participants in each group. We considered a two-sided <math>\alpha</math> value of less than 0.05 significant with no adjustments made for multiple comparisons. We used the IPDA and d3PCR assays as our primary reservoir measurement as intact proviral DNA is superior to total HIV-1 DNA in terms of estimating the intact HIV-1 reservoir<sup>6</sup>. Protocol amendments did not affect the analysis plan besides the reservoir size analyzes described above.</p>
Data exclusions	No data were excluded.
Replication	This study was a clinical trial and the analyses were performed on individual trial participants. Experiments did not include replicates as all participants and data points are unique. All available data is included in the manuscript.
Randomization	The Clinical Trial Unit at Aarhus University generated the randomization sequence using permuted blocks of 4 or 8 by computer-generated random numbers. Randomization assignment was provided to each site through using REDCap.
Blinding	Participants, study physicians and nurses handling administrations of the study drugs as well as those doing the analyses were blinded to interventions. Only pharmacy and study personnel preparing the study drugs were unblinded to interventions.



# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

## Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

3BNC117 and 10-1074 are investigational anti-HIV-1 neutralizing antibody manufactured for clinical use. 3BNC117 is being investigated under US FDA INDs 118225 and 123713, respectively.

In the AIM assay, the following antibodies were used:  
 CD3 (PerCP/Cy5.5 anti-human CD3, SK7, BioLegend)  
 CD4 (BV650 anti-human CD4, RPA-T4, BioLegend)  
 CD8 (BV605 anti-human CD8a, RPA-T8, BioLegend)  
 4-1BB (PE anti-human CD137, 4B4-1, BioLegend)  
 CD69 (APC anti-human CD69, FN50, BioLegend)  
 PD-L1 (BV421 anti-human CD274, B7-H1, BioLegend)  
 OX40 (FITC anti-human CD134, Ber-ACT35 (ACT35), BioLegend)

### Validation

3BNC117 and 10-0174 that were administered to the participants were manufactured by Celldex Therapeutics under Good Manufacturing Practice and has been fully characterized in terms of biophysical properties and potency (INDs 118225 and 123713). 3BNC117 and 10-1074 are under long-term stability monitoring.

3BNC117: Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* 333, 1633–7 (2011).  
 10-1074: Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proc. Natl. Acad. Sci. U. S. A.* 109, E3268-77 (2012).

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

### Clinical trial registration

Clinicaltrials.gov: NCT03837756, EudraCT number: 2018-001165-16.

### Study protocol

TITAN-001, verison 3.0, 02 July 2021.

### Data collection

Eligible individuals were recruited from 12 April 2019 to 05 November 2021, and the last follow-up visit occurred on 09 June 2022.

Study data were collected and managed in Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Clinical Trial Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

### Outcomes

The primary endpoint was 1) time to loss of virological control during ATI. We defined loos of virologic control as sustained plasma HIV-1 RNA  $\geq 1000$  copies/mL for 4 weeks or confirmed  $>100,000$  copies/mL. Secondary endpoints were 1) safety including CD4+ T cell counts, and 2) viral kinetics during ATI: time to plasma HIV-1 RNA  $>50$  and  $>1,000$  copies/mL as well as doubling time of the initial increase in plasma HIV-1 RNA. Exploratory endpoints were 1) changes in reservoir size measured by intact HIV-1 proviruses, and 2) effects on HIV-1-specific T-cell imunity using the AIM assay.

## Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

Sample preparation

AIM: Cryopreserved PBMCs were thawed, washed and rested at 37C for 3 hours. Cells were then plated into wells of a 96-well plate, at a total of  $1 \times 10^6$  cells per well and stimulated with the different conditions. Following 20 hours incubation at 37C, cells were washed with PBS and stained for viability for 20 minutes. Cells were then incubated with Human TruStain FcX in PBS 2% FBS for 10 minutes and stained 30 minutes with surface markers antibodies. Cells were washed twice and acquired.

Instrument

MACSQuant® Analyzer 16 Flow Cytometer (Miltenyi Biotec)

Software

Flow cytometry data were analyzed using FlowJo software, version 10.7.1 (Tree Star).

Cell population abundance

No sorting was performed.

Gating strategy

Live cells > single cells > lymphocytes > CD3+ cells > CD4+ and CD8+ cells. The frequency of antigen-specific cells (AIM+ cells) was determined by subtracting the frequency of the non-stimulation condition from the antigen stimulated conditions (Gag, Env, Nef and Pol). Gag-specific AIM+ cells were considered as the addition of the frequency of cells that were either CD69+PD-L1+4-1BB+OX40+, CD69+PD-L1+OX40+, 4-1BB+OX40+PD-L1+, CD69+PD-L1+4-1BB+, OX40+CD69+4-1BB+, CD69+PD-L1+, CD69+4-1BB+, OX40+PD-L1+, CD69+OX40+, 4-1BB+OX40+ or PD-L1+4-1BB+. Total HIV-specific AIM+ cells was calculated as summation of each of the 11 populations for the four antigen-stimulations.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.